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Abstract 
Altered metabolism of cancer cells provides new therapeutic strategies for 
anticancer treatment. Cancer cells preferentially select glycolysis and lactic acid 
fermentation for their metabolic requirements, even in the presence of sufficient 
oxygen. Targeting cancer cell metabolism gave promising results as the treatments are 
offering therapeutic selectivity in the name of killing cancer cells more effectively while 
sparing normal cells. Coupling glycolysis inhibition with chemotherapy is one of the 
new strategies against cancer.  
In this thesis, we have studied with colon cancer cell lines HCT 116 WT, p53-/- 
and Bax-/-. Glycolysis inhibition was achieved with a glucose analog, 2-Deoxyglucose 
(2-DG) which is at the stage of clinical trials. Cisplatin and TNF-related apoptosis-
inducing ligand (Killer TRAIL) were selected as anticancer agents. Pretreatment of 2-
DG prior to cisplatin and Killer TRAIL treatment sensitized the cells to apoptotic cell 
death induced by these anticancer agents and increased cell death numbers. We 
observed several mechanisms to this sensitization effect. 2-DG sensitizes the cells to 
cisplatin and Killer TRAIL-induced apoptosis via downregulation of a crucial 
antiapoptotic protein Mcl-1, belonging to the Bcl-2 protein family. ATP depletion due 
to inhibition of glycolysis and cell cycle arrest are other contributing mechanisms. 2-DG 
also caused activation of energy biosensor AMPK and inhibition of cell growth and 
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protein synthesis regulator mTOR. For a detailed analysis of 2-DG’s effects on the gene 
level, RNA microarray study was conducted. The results of this study harmonized with 
the data indicated. 
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ÖZET 
 DeğiĢen kanser metabolizması kanser tedavisinde yenilikçi bir terapötik tedavi 
stratejisi vaad etmektedir. Kanser hücreleri metabolik gereksinimlerini yeterli oksijen 
altında bile özellikle glikoliz ve laktik asit fermantasyonu yoluyla yaparlar. Kanser 
metabolizmasını hedeflemek kanser tedavilerinde terapötik bir seçicilik sunarak kanser 
hücrelerini daha fazla öldürürken normal hücreleri az oranda etkileme fırsatı 
sunmaktadır. Bu sebeple glikoliz inhibitörlerinin kemoterapi ile birlikte tedavi amaçlı 
sunulması kansere karĢı yeni tedavi stretejilerindendir. 
 Bu tez çalıĢmasında kolon karsinoma hücre hatları HCT 116 WT, p53-/- ve Bax-
/- kullanılmıĢtır. Glikolizin önlenmesi için glikoz benzeri bir molekül olan 2-
Deoxyglucose kullanılırken, antikanser ajanları olarak sisplatin ve TNF-bağlantılı 
apoptozu indükleyen TRAIL molekülü seçilmiĢtir. Hücrelerin sisplatin ve TRAIL ile 
olan muamelesinden önce bir ön muamele olarak sunulan 2-Deoxyglucose hücreleri bu 
antikanser ajanlarının sebep olduğu apoptoza karĢı hassaslaĢtırmıĢ ve ölüm oranlarının 
artmasına sebep olmuĢtur. Bu duyarlı hale getirme durumu ile ilgili bir takım 
mekanizmalar belirlenmiĢtir. Buna göre, 2-Deoxyglucose hücreleri belirlenen antikanser 
ajanlarının sebep olduğu apoptoza karĢı hassaslaĢtırırmayı Bcl-2 protein ailesinin 
apoptoz karĢıtı önemli bir üyesi olan Mcl-1’in protein düzeyinde düĢüĢe sebep olarak 
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baĢarmaktadır. ATP üretiminde meydana gelen azalma ve hücre döngüsü içinde oluĢan 
G1 fazındaki durma hassaslaĢtırma etkisine katkıda bulunan diğer mekanizmalardır. 
Ayrıca, 2-Deoxyglucose biyosensör AMPK’nin aktivasyonuna ve hücre büyümesi ve 
protein sentezi regülatörü mTOR’un inhibisyonuna sebep olmuĢtur. Daha detaylı bir 
bakıĢ için, genlerin ekspresyonlarındaki değiĢimleri incelemek adına RNA mikroarray 
çalıĢması düzenlenmiĢ ve sonuçlarının deney verileri ile örtüĢtükleri görülmüĢtür. 
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1. INTRODUCTION 
 
 
1.1 The Warburg Effect: Cancer Cell Metabolism 
 
 
 The word ‘metabolism’ is of Greek origin and it basically means ‘a process of 
change’. In this context, its use is not different considering that we are dealing with the 
smallest living units, the cells of an organism. The cells in which happens enormous 
changes each and every second, from the continously active chemical processes to 
physical ones. The sum of it all keeps the cell or, in a broader sense, the organism alive.  
Cellular metabolism has always been an interesting study of biochemical 
research. Especally if we are talking about cancer cells. In recent years cancer cell 
metabolism has become the hot topic it once was. Going back to the intial hypotheses 
on what a cancer cell’s metabolic needs are, metabolic alterations have proven to be 
crucial and important. Starting with Otto Warburg in 1920s and later with his 
contemporaries, cancer is linked to altered metabolism (1). However, the promising 
findings at the time were left in the shadow of the popular, new and complex oncogene 
revolution. It is ironic that may be it is time for oncogene revolution to take a back seat 
because the old and relatively easier study of cancer cell metabolism is about to take a 
hold. 
Otto Heinrich Warburg, now remembered as one of the twentieth century's 
leading biochemists, found that cancer cells undergo a change in their energy 
metabolism, which is rather different from the usual condition of the normal cells. 
According to his studies, cancer cells show increased glucose consumption and they 
prefer fermentation over respiration for their metabolic needs (2, 3). This was very 
interesting considering these cells going for lactic acid fermentation even under 
sufficient oxygen and showing higher glucose uptake. As it is about to be explained in 
details, this crucial metabolic shift from the normal oxidative breakdown to the non-
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oxidative breakdown of glucose gives benefits to cancer development and is widely 
accepted as a phenomenon underlying the most common phenotype of cancer cells (4). 
 
 
 
 
 
 
 
 
 
 
 
 This key molecular event, named after Otto Warburg as the ‘Warburg Effect’, 
benefits cancer in terms of the following (4): The glycolytic pathway serves as a rich 
source of carbon precursors for the biosynthesis of macromolecules that are needed as 
building blocks for a cancer cell dividing rapidly. It helps for a cancer cell’s protection 
and rapid growth, providing an acidic surrounding(lactic acid fermentation) making it 
easier to invade neighbouring cells. And it eliminates a cancer cell’s dependance on 
oxygen, meaning that the cell can continue to survive under oxygen deficient 
conditions. 
 But to realize the significance of the Warburg Effect, we should first understand 
cellular metabolism i.e. cellular needs such as energy generation and macromolecule 
biosynthesis. Then we will be able to see the complete picture of how cancer cells differ 
from normal cells in terms of their metabolic requirements. 
 
 
Figure 1. 1 Otto Warburg won the Nobel Prize in 1931 for his studies on cellular metabolism. 
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1.1.1 Understanding Cellular Metabolism: What A Cell Needs? 
 
Glucose is an important molecule for mammalian cells in terms of its being rich 
in potential energy thus an excellent fuel and of its serving as a versatile precursor 
providing metabolic intermediates for biosynthetic reactions (5):  
In order to obtain energy from processing glucose, these cells have two options. 
Either going for aerobic respiration(oxidative phosphorylation) or choosing lactic acid 
fermentation considering the absence of oxygen. However glucose should first go 
through ‘glycolysis’, a crucial central pathway of glucose catabolism. Glycolysis can be 
explained as six-carbon glucose molecule undergoing a series of enzyme-catalyzed 
processes to give out two three-carbon products named pyruvate (FIG. 1.2). This 
process gives the cells a net gain of 2 molecules of ATP and the product(pyruvate) is 
ready for oxidative breakdown to yield more energy. From there on pyruvate gives out 2 
molecules of Acetyl-CoA and they enter citric acid cycle (aka Krebs cycle, TCA cycle) 
to finally produce 4 molecules of both carbon-dioxide and water and overall generating 
up to 36 ATPs from one complete oxidation of a glucose molecule. That is basically 
what a mammalian cell does in order to satisfy its energy need in an aerobic condition. 
However there is also lactic acid fermantation standing as the other option but it is 
preferred mostly in anaerobic conditions other than some specific cell types such as 
contracting muscle cells and erythrocytes. But lactic acid fermentation is nowhere near 
oxidative phosphorylation in terms of providing energy as the only ATP gain comes 
from glycolysis. 
Apart from both of these depending on the presence or absence of oxygen, there 
is another process called aerobic glycolysis which is like a mixture of both but relying 
on lactic acid fermentation much more. Therefore most of the pyruvate produced from 
glycolysis process into lactate leaving very little to enter mitochondria. The overall 
energy gain is a bit more than the usual lactic acid fermentation, giving out 
approximately 4 molecules of ATP(6) (FIG. 1.3).  
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The important thing here is that with or without oxygen the cells undergoing 
aerobic glycolysis don’t necessarily go for oxidative phosphorylation. Yes it gives out 
far less ATP but is that really a problem? Well, actually it is not. Because the cells 
choosing this aerobic glycolysis do choose it for some interesting benefits. The ATP 
Figure 1. 2 Glycolysis followed by either Aerobic Respiration or 
Lactic Acid Fermentation 
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production is never a problem when you have a continuous availability of resources as 
glucose and nutrients in circulating blood.  
 
 
Figure 1. 3 Energy gaining processes: Oxidative Phosphorylation, Anaerobic 
Glycolysis and Aerobic Glycolysis 
 
Higher glucose uptake and faster glycolysis remedy the deficiency of ATP production 
and thus the problem is solved. Think of a cell undergoing glycolysis successively in an 
aggressive manner in order to gain as much ATP as a normal cell easily gains from 
oxidative phosphorylation. 
 But what are the benefits of switching to aerobic glycolysis? Why cells choose 
it? Because they have some significant metabolic requirements i.e. macromolecule 
biosynthesis for the build up. What we should consider now is that we are now talking 
6 
 
about cells which are proliferating or cancerous as both show this switch and their 
requirements differ from that of differentiated(non-proliferating) cells. Proliferating 
cells and cancer cells need rapid cell division and with aerobic glycolysis they 
incorporate carbon into biomass faster providing useful intermediates for biosynthesis. 
For example, instead of going through oxidative phosphorylation acetyl-CoA, an 
important macromolecular precursor, is used for lipid synthesis while some other 
glycolytic intermediates  serve for amino acid and nucleic acid synthesis(6, 7). These 
cells also use TCA cycle as a center for biosynthesis rather than using it for maximal 
ATP production, so it is actually the other way around as in TCA cycle they consume 
ATP(7). 
 Cancer cells show high resemblance to proliferating cells in terms of metabolic 
requirements and this is basically because of their needs for rapid division. Cell 
proliferation is the increase in cell number due to cell growth and division. Mammals 
require cell proliferation for embryogenesis, growth, proper functioning of tissues and 
tumorigenesis(7). And for a cell to proliferate it must respond to the needs as the onset 
of proliferation brings serious changes. The cell enters the cell cycle, undergoing a 
heavy work of synthesis as they require to double their biomass in order to provide for 
the two daughter cells. The divergence between the normal proliferating cells and 
cancer cells comes with genetic alterations and some changes in cellular 
microenvironment(8). And also the ability of normal proliferating cells to come back to 
the resting state switching back to an oxidative metabolism unlike cancer cells(9). 
Therefore, to understand the reasons behind cancer cell metabolism and to think over 
the possible biological causes, it is best to go over the mechanistic perspectives of the 
Warburg effect. 
 
 
1.2 The Mechanistic Perspectives of The Warburg Effect 
 
 
At this point we know more or less what basically the Warburg Effect is. 
However, to go deeper in the understanding of it and to realize the exact reasons behind 
this phenomenon we need to elaborate on the mechanistic perspectives that give us 
information on the potential causes as to why cancer cells go for increased glycolysis. 
The perspectives can be explained under four different subtitles having crucial aspects 
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about their possible contributions to the Warburg effect as for each there are evidences 
sustaining them(10)(FIG. 1.4). 
 
 
 
 
 
 
 
 
 
 
Figure 1. 4 Mechanistic perspectives of the Warburg effect. 
 
1.2.1 Hypoxia 
 
Hypoxia is a condition of having low levels of oxygen, often too low holding a 
threat against the proper functioning of cellular metabolism. Normally, cells rely on 
oxidative phosphorylation to fulfill their energy needs but when there is inadequate 
amounts of available oxygen they switch to the glycolytic phenotype that is basing their 
metabolic reqirements on glycolysis(11). 
With studies like Warburg’s research(2) on alteration of cellular metabolism 
independent of oxygen levels and Thomlinson and Gray’s observation(12) of hypoxia in 
human lung cancer cells, hypoxia is mentioned among one of the special attributes of 
these cells.  But what exactly is the reason behind the formation of  hypoxic regions? 
Tumors’ rapid expansion culminate in poorly formed tumor vasculature(13, 14). The 
vascular system of an organism is responsible for the transportation of oxygen and 
nutrients to the tissues, but in this context the blood vessels around tumor show aberrant 
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function(15, 16). This causes a selection among cells, distinguishing the ones that are 
able to respond and adapt to this condition. This is why tumor cells change their 
metabolism(Warburg Effect) to fit into the new environment, to survive in the new 
circumstances. This adaptation occurs with the activity of hypoxia-inducible-factor 1 
(HIF1), a transcription factor controlling many other hypoxia related genes; stimulating 
the transcription of glycolytic enzymes, glucose transporters, survival and growth 
factors and so on(17). 
 
 
1.2.2 Tumor Microenvironment 
 
The metabolic microenvironment of tumors comes up with another characteristic 
along with hypoxia, which is lactic acidosis due to the upregulation of glycolysis. Lactic 
acid fermentation provides the acidic environment as these cells produce and transport it 
out causing an acidic extracellular condition(4). The low pH values contribute to 
Warburg effect in the sense that it gives cancer cells an immense growth advantage 
promoting their proliferation and invasion, and that might express why these cells alter 
their metabolism to benefit from this.  Also lactate might play a role as a signaling 
molecule setting up a substructure for the alteration of metabolism(18). With the 
inductions of various cellular stress responses, adapting to these harsh environments 
further contributes to the distorted metabolic phenotype(1). 
 
 
1.2.3 Defects in Mitochondria 
 
Mitochondria are membrane enclosed organelles responsible for the production 
of power for eukaryotic cells. As the energy centers, the powerhouses, mitochondria are 
essential. The possible problems occuring in them can cause serious issues and major 
changes. In this sense, mitochondrial defects can play an important role in switching to 
glycolytic phenotype.  It was Warburg again in the early 20th century proposing that 
cancer cells have defects in mitochondria, as he related that the giving up on oxidative 
phospshorylation might mean some kind of a complication(19, 20, 21). The probable 
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complications causing a defective mitochondria include mitochondrial DNA mutations 
due to free radicals; decreased efficiency of TCA cycle because of inappropriate 
intermediates; enzymatic dysfunctions and the decomposition of mitochondrial 
membrane(22). 
This idea, overall, was rejected in the beginning and used against Warburg 
following the publications of his results(9): In 1956, Weinhouse rejected the possibility 
of a permanent respiratory problem(23) basing his arguments onto their finding of the 
ability to increase the OXPHOS activity of neoplasias when supplemented with 
NAD(24). Supporting Weinhouse results, in 2004 Russignol et al. showed that 
OXPHOS activity can be increased in cancer cells ruling out the discussions of 
irreversible impairment(25). However, some recent articles state mitochondrial 
defects(being not necessarily an irreversible impairment) as a potential reason behind 
cancer cells’ increased glycolytic rate with the idea of mitochondrial dysfunction due to 
high levels of ROS production(26), mitochondrial DNA mutations(27) and 
uncoupling(28). 
 
 
1.2.4 Oncogenic Signals 
 
 Another significant mechanistic perspective of the Warburg effect is the 
oncogenic signals that are driving the changes in metabolism, directly controlling it 
through signaling pathways involving known oncogenes and tumor suppressor genes(6) 
(FIG. 1.5). 
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Figure 1. 5 List of some known oncogenes and tumor suppressor genes related to The 
Warburg Effect 
 
Oncogenes of the PI3K/Akt/mTOR pathway, c-Myc and hypoxia inducible 
factors; tumor suppressors AMP-activated protein kinase and p53 are among the 
important genes having their names put on the map of the Warburg effect. These genes 
have significant effects over cellular metabolism, growth and proliferation. The next 
chapter, Molecular Mechanisms driving the Warburg Effect, will put the emphasis on 
three of these genes being mammalian target of rapamycin (mTOR), AMP-activated 
protein kinase (AMPK) and tumor suppressor p53.  
 
 
1.3 Molecular Mechanisms driving The Warburg Effect 
 
 
With the recent advances in genomics and proteomics, it is now easier to look 
into molecular mechanisms that contribute to the Warburg effect and tumorigenesis. 
The point being that the provided molecular insights enlighten us about the many 
aspects of the Warburg effect and how to use it against the cancer itself for cancer 
therapy(29). 
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1.3.1 AMPK: Adenosine monophosphate (AMP)-activated protein kinase 
 
AMPK is a serine/threonine protein kinase getting activated by cellular stress 
condi-tions resulting in the depletion of ATP. Under the conditions of increased 
AMP/ATP ratio, AMPK responds to prevent ATP consuming pathways and activate the 
ones that are responsible for ATP generation(30). The importance of AMPK comes 
from the fact that it is found in all eukaryotes and it senses the cellular energy status 
regulating the energy balance. Being highly conserved as a heterodimer, it comprises a 
catalytic subunit and regulatory andsubunits, apart from the structural information 
of the AMPK protein these also give us the understanding of its current model for 
activation(31, 32): with the decrease in ATP levels and increase in AMP, AMP goes 
and binds to nucleotide binding domains in the AMPK subunit eventuating in a 
conformational change in the heterodimer revealing the activation loop of the catalytic 
subunit. Phosphorylation of a critical threonine in this loop does the job needed for 
the activation of AMPK. 
The AMPK activity is linked to tumor progression with the understanding of its 
controlling some processes standing in connection to development of tumors, cell 
growth, proliferation and protein translation(33). As a low energy checkpoint, tumor 
cells have to overcome this to achieve proliferation in response to activated growth 
signaling pathways. Most of the time with oncogenic mutations and with other signaling 
pathways many cancer cells manage to hold back AMPK signaling. Alteration of 
metabolism is closely related to AMPK activity as the loss of it results in the activation 
of mTOR and HIF1, helping for the switch into the glycolytic phenotype and the 
proliferating status(1). AMPK itself appears to have a role also in protein synthesis as it 
phosphorylates and inactivates eEF2 kinase which in turn causes an inhibition of protein 
synthesis(34). 
With the recent growing interest in AMPK signaling and the idea to use it 
against tumor progression, we have started to see the term ‘AMPK activation’ among 
cancer related articles dealing with Warburg effect and cancer cell metabolism(35, 36). 
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1.3.2 Mammalian Target of Rapamycin (mTOR) Pathway 
 
Playing a key regulatory role in cell growth, proliferation and differentiation, 
mammalian target of rapamycin (mTOR) has been investigated intensely for its effects 
in tumor development and progression(37). As an evolutionarily conserved serine 
threonine kinase and a part of a crucial signaling ensemble involving insulin like growth 
factor-I receptor (IGFR), phosphatidylinositol 3-kinase (PI3K), protein kinase B 
(Akt/PKB) cons-tituting the IGFR-PI3K-Akt-mTOR signaling pathway, mTOR has 
been shown abnormally activated in various transformed cells and human tumors(38, 
39). The dysregulation of mTOR signaling causes a favorable oncogenic environment 
for cancer and the activation of mTOR brings about a series of downstream 
consequences helping for the metabolic reprogramming. 
mTOR’s most distinguished functions are its controlling of protein synthesis at 
several levels and its enhancing of ribosome biogenesis. It phosphorylates and activates 
ribosomal kinase p70 S6K and this in turn activates some downstream targets to initiate 
translation. mTOR also phosphorylates eukaryotic initiation factor 4E binding proteins 
(4E-BPs) causing their release from eukaryotic initiation factor 4E (eIF4E) making 
space for translation initiation factors to bind and  stimulate translation properly(37, 40) 
(FIG. 1.6). Thinking about a possible abnormal functioning such as a highly active 
mTOR, an increase in protein synthesis overall gives us a clue as to how mTOR 
pathway favor anabolic cell growth and proliferation in tumor cells(41). 
Another feature of the mTOR pathway is that it promotes the expression of 
genes supporting the glycolytic phenotype, those genes being HIF1 and c-Myc 
mainly(6, 42, 43). This also gives an idea about mTOR’s role in cancer development 
showing of decisive importance in many aspects. 
mTOR, with all these significant activities, holds a great promise for anti-cancer 
mechanisms and cancer therapy. mTOR inhibitors have been used as therapeutic agents 
against cancer. Rapamycin is a well known mTOR inhibitor having the mechanism for 
cancer therapy as it’s causing an inhibition of protein sythesis to an extent(~5% 
reduction) and resulting in G1 cell cycle arrest and leading cells to apoptosis(38). 
However, recent clinical updates state that rapamycin is effective over only a few 
cancers and the therapeutic response to it is highly variable(44). 
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Figure 1. 6 AMPK-mTOR relation and mTOR Pathway (simplified) 
 
1.3.3 Tumor Suppressor p53 
 
Known as the ‘Guardian of the Genome’, p53 is a highly important tumor 
suppressor having critical roles in cellular metabolism, differentiation, cell cycle control 
and apoptosis. Inactivation of the p53 tumor suppressor pathway is one of the most 
common features detected in cancer considering the responses provoked by p53 such as 
inhibition of cell growth, cell cycle arrest and cell death in order to prevent tumor 
formation(45). However, recently its role in cell metabolism has gained a renewed 
interest and studies provide interesting findings about the energy generating metabolic 
pathways and their regulation by p53 (FIG. 1.7). This of course revealed p53’s 
importance in terms of the Warburg effect(46). 
TP53-induced glycolysis and apoptosis regulator (TIGAR) is one of the proteins 
involving in glycolysis and being regulated by p53(47, 48). In a 2006 dated paper, 
Vousden and his colleagues showed that p53-induced TIGAR expression causes a 
decrease in fructose-2,6-biphosphate levels inhibiting glycolysis and regulates apoptosis 
in a cell-type dependent manner. This is actually consistent with recent studies stating 
that the modulation of glycolytic rates can have a profound effect on the apoptotic 
sensitivity of cells, especially cancer cells(6).   
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Figure 1. 7 p53 and Metabolism 
 
 Another insight into p53’s effect on the mode of energy production comes with 
its regulation of an important assembly protein encoded by the ‘synthesis of cytochrome 
c oxidase 2 (SCO2)’ gene(49). SCO2 is required for the assembly of the cytochrome c 
oxidase (COX) complex inside the inner mitochondrial membrane that is the major site 
of oxygen use in mammalian cells. p53 regulates aerobic respiration through SCO2 with 
this controlling mechanism inside mitochondria(50, 51). Another mitochondrial control 
mechanism of p53 is the ribonucleotide reductase subunit p53R2. p53 regulates its 
expression whose responsibility is the maintenance of mitochondrial DNA and a 
possible loss causes a decrease in mitochondrial DNA and leads to dysfunction(52). 
 p53 also has a regulatory role along with HIF-1 over hexokinases, especially the 
isoform HK2 expressed in cancer cells. HK2 is an enzyme, a primary initiator of 
glycolysis phosphorylating glucose to glucose-6-phosphate thereby starting the 
glycolytic process(53). 
 Altogether p53 works as a tumor suppressor by all means, from its negative 
regulation of glycolysis to its induction of apoptosis for the elimination of cancer cells. 
However, dominating a huge network of various signaling pathways, p53 signaling is 
not yet clear. It has a contradicting nature giving out results like enhancing apoptosis in 
a condition and working against it in another, hindering glycolysis but also enhancing 
some of its steps and so on. p53 definitely deserves to be called the ‘guardian’. For this 
matter, especially in cancer cells, loss of p53 signaling initially serves for the metabolic 
change driving the Warburg effect, however p53 is helping them for undergoing the 
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metabolic adaptation as well. Maddocks and Vousden described the situation as a 
‘double edged sword’ meaning that p53 deficiency may also sensitise tumor cells to 
metabolic stress(54). A study in 2008 provided an interesting aspect as the wild-type 
p53 in breast cancer cells induces cell cycle arrest and therefore protecting tumor cells 
from cytotoxic damages which overall leads to reduced therapeutic response and poor 
prognosis(55). 
 
 
1.4 Targeting The Warburg Effect 
 
 
Targeted therapeutics directed against cancer mostly rely on  killing cancer cells 
with nonsurgical methods of cancer treatment such as radiation therapy and 
chemotherapy. The common problem in these treatments is that most of these anticancer 
agents do not have specificity for cancer cells as they also kill healthy and normal cells 
along the way, even in the radiation therapy where a degree of specificity is achieved 
through with localizing the radiation to the tumor(56). 
With the recent studies on targeting cancer aiming for improved effectiveness, 
tumor physiology gained a lot of attention with the idea of exploiting the cellular and 
molecular differences between cancerous and normal cells and to use it for an 
alternative, selective cancer treatment(56, 50). Targeting the Warburg effect as an 
anticancer strategy suggest several potential therapeutic avenues. Glycolysis inhibition, 
especially, holds great promise as targeting the seventh hallmark of cancer(53), 
glycolysis, is also one of cancers’ most vulnerable phenotypes. 
 
 
1.4.1 Glycolysis Inhibition for Anticancer Treatment 
 
Glycolysis inhibition is one important targeting mechanism against cancer 
metabolism. There are two mechanisms considering the glycolytic phenotype: Either 
targeting upstream regulators being HIF, PI3K, Akt, mTOR and AMPK or targeting the 
glycolytic pathway, the key metabolic enzymes critical for bioenergetic supply(57). The 
idea behind glycolysis inhibition is to use it against cancer while sparing normal tissues 
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because cancer cells show high glucose uptake and a huge increase in glycolysis. Here 
are some of the glycolytic enzymes  as potential therapeutic targets(58, 59)(FIG. 1.8): 
Hexokinase is a mitochondria associated enzyme of the first rate limiting step of 
glycolysis, phosphorylating glucose to glucose-6-phosphate. Among the four isoforms 
(Hexokinase I-IV), Hexokinase II is overexpressed in many cancer cells, playing the 
role in initiating and maintaining the high glycolytic rates(60, 61). HK2 might also be 
having a role in apoptosis regulation, along with its enzymatic activity(62). Robey and 
Hay, in their 2006 dated paper, claimed mitochondrial hexokinases as novel mediators 
of apoptosis stating their anti apoptotic properties(63). These features of HK2 make it 
an attractive target. Three known compounds used against HKs are 2-Deoxyglucose, 3-
Bromopyruvate and Lonidamine: 2-Deoxyglucose (will be covered in details shortly) 
inhibits phosphorylation of glucose by HK,: 3-Bromopyruvate is an alkylating agent 
and it inhibits HK; Lonidamine works against glycolysis by dissociating HK from 
mitochondria thus inhibiting both glycolysis and mitochondrial respiration(59). 
6-Phosphofructo-1-kinase (PFK) converts fructose-6-phosphate to fructose-1,6-
bisphosphate. Four enzymes from PFKFB (1-4) family are responsible for this 
conversion. Especially PFKFB3 is a target of HIF-1, promoting glycolysis. One study 
showed that the inhibition of PFKFB3 resulted in suppression of glycolysis and tumor 
growth(64). 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) catalyzes the sixth step 
of glycolysis. Arsenic is a known inhibitor. Recently GAPDH has been implicated in 
the initiation of apoptosis(65). This enzyme can be a crucial target like HK2, 
considering its roles in both glycolysis and apoptosis. 
Pyruvate kinase is another important enzyme of the glycolytic pathway, 
producing pyruvate, the end product of glycolysis. This enzyme is known to be 
regulated by HIF-1 and Myc, especially the splicing variant PKM2 has been linked to 
cancer metabolism contributing to the Warburg effect(58). 
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Figure 1. 8 Targeting the Glycolytic Pathway 
                                                  
Another target gene of HIF-1 and Myc is lactate dehydrogenase-A (LDHA) 
being the enzyme responsible for the conversion of pyruvate to lactate. Oxamate is used 
as a metabolic inhibitor against it.  LDHA has been shown to be crucial for 
tumorigenesis with several studies, knowing its significance in lactic acid fermentation 
thus altered cancer metabolism(66). And two recent studies in 2006 and 2010 
respectively stated that LDHA inhibiton causes oxidative stress and restrains tumor 
progression(67) and knockdown of LDHA severely diminishes tumorigenicity(68). 
Pyruvate dehydrogenase (PDH) is the enzyme at the decision step whether the 
cell goes for oxidative phoshorylation or lactic acid fermentation because it serves for 
the conversion of pyruvate to acetyl CoA and therefore opening the way for oxidative 
phosphorylation. However, pyruvate dehydrogenase kinase (PDK) have the ability to 
inactivate PDH, empeding the progress of acetyl CoA production and supporting lactate 
formation. Inhibiting PDK can be effective for anticancer treatment(58). 
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1.4.1.1 Glycolysis inhibition by 2-Deoxyglucose (2-DG) 
 
2-DG is an anti metabolic glucose with the difference of having a hydrogen 
instead of a hydroxyl group at the carbon in the second position. This rare, natural 
monosaccharide is known to inhibit glucose metabolism via acting as a competitive 
inhibitor. Once it gets inside the cells, it undergoes phosphorylation by hexokinase 
forming 2-DG-P which can not be metabolized in the next steps(59).  
2-DG has come into prominence with every study from various prospects 
examining the physiological and pharmacological effects. Starting as a low glucose 
mimetic it has now been regarded as a promising anticancer and antiviral therapeutic. 2-
DG earned its reputation as a possible anticancer compound with its inhibitory effect 
over glucose metabolism causing a mild depletion of ATP and its giving rise to 
problems in protein synthesis by disrupting protein glycosylation and ER quality 
control(69). 2-DG’s effect on protein glycosylation is not well examined, only a couple 
of studies are there for this topic and they explain that 2-DG causes accumulation of 
misfolded proteins in ER and induces ER stress response(70, 71). 
Glycolysis inhibition by 2-DG in tumor cells gave results such as decrease in 
ATP levels, cell cycle block and cell death according to Maher et al.(72). Zhu et al. 
contributes to this by indicating 2-DG induction of a dose- and time-dependent 
reduction in cell growth and energy levels in vitro(73). However, administration of 2-
DG alone, even though high doses up to 250mg/kg appears safe for use(74), actually do 
not show significant anticancer activity in vivo. Its cytotoxic effects are varied among 
different tumor cell lines and there is also this fact that its effectiveness decreases in the 
presence of glucose leading to a partial inhibition (75, 59). Altogether, 2-DG does not 
lose any significance because its combination with chemotherapy and radiotherapy 
comes into the picture. 
 
 
1.4.1.2 Combination of glycolytic inhibition and other anticancer agents 
 
Even though 2-DG monotherapy is not that effective against tumor growth, its 
combination with chemotherapy and radiotherapy gave successful results in terms of 
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sensitization of cancer cells to anticancer agents(76). 2-DG treatment studies have given 
results announcing chemosensitizing and cytotoxic effects of this treatment as well as 
causing potentiation of chemotherapeutic drugs such as etoposide, ellipticine, cisplatin, 
carboplatin, 5-fluorouracil, doxorubicin, herceptin and cyclophosphamide(77, 78, 79). 
2-DG also showed radiosensitization effect in a couple of studies(80, 81), and its 
combination with apoptosis inducers(82, 83) and with some other glycolytic inhibitors 
at once offer potential cancer treatments(84, 85). However, the actual network of this 
sensitization effect, and how exactly 2-DG potentiates these anticancer drugs is still not 
well known and in need of further examination and confirmation despite some recent 
studies(86, 87). 2-DG is now in clinical trials. 
 
 
1.5 Apoptosis, as an Anticancer Strategy 
 
 
In the context of cancer prevention and control, apoptosis is an essential cellular 
response happening constantly in mammals, killing and replacing damaged and harmful 
cells each second. It is vital to have a proper apoptotic signaling against aberrant cell 
proliferation and accumulation of genetic defects which undoubtedly provoke 
tumorigenesis(88).  
Apoptosis occurs through three phases(89): First is the induction phase in which 
a signal is originated  either extracellularly or intracellularly initiating the death of the 
cell. Extracellular signals can be toxins, growth factors, hormones or any other ligand 
binding to cell surface death receptors; whereas intracellular triggering of apoptosis is 
achieved when there is a stress condition such as DNA damage, hypoxia, nutrient 
deprivation, heat etc. Following the initiation, the effector phase takes place as the cell 
receives the signal and prepares to take action. In this phase, regulators (such as Bcl-2 
proten family) and effectors (caspases) of apoptosis get to work to adjust the apoptotic 
signaling mechanisms. Then comes the third and final phase witnessing the degradation 
of the cell, undergoing shrinking, membrane blebbing, organelle relocalization and 
chromatin condensation ending up with the formation of apoptotic bodies, finishing the 
job. 
As an anticancer stragetegy the majority of chemotherapeutic agents as well as 
radiation utilize the apoptotic pathway to kill cancer cells. To understand the basic 
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mechanisms, we will now look at the extrinsic and intrinsic apoptotic pathways and 
cover the regulators and effectors of apoptosis(FIG. 1.9). 
 
 
1.5.1 Extrinsic and Intrinsic Apoptotic Pathways 
 
The extrinsic apoptotic pathway begins with the activation of death receptors on 
the cell surface. Upon the binding of a death inducing ligand to its receptor such as TNF 
to TNF receptor 1, FAS ligand to FAS receptor, TNF-related apoptosis inducing ligand 
(TRAIL) to TRAIL receptors 1 and 2, there happens a conformational change in the 
intracellular domains of the receptors revealing the death domain which serves for the 
recruitment of a varity of apoptotic proteins to the receptor and the formation of a 
complex called Death Inducing Signaling Complex (DISC). DISC is responsible for the 
activation of caspase 8, initiating the caspase cascade(88). 
The intrinsic apoptotic pathway, on the other hand, is induced by the integration 
and propagation of death signals originating from inside the cell such as DNA damage, 
hypoxia, oxidative stress, starvation and so on. Following the stress condition, 
mitochondria plays the leading role in the process as it causes the release of 
proapoptotic proteins into the cytosol. The electron carrier protein cytochrome c 
initiates the events once it gets into the cytosol upon the disruption of the mitochondrial 
outer membrane, then it goes and binds to an adaptor protein named Apaf-1, activating 
it. Activated Apaf-1 opens the way for procaspase activation by binding to procaspase 9 
leading to the caspase cascade(90). 
Both pathways use caspase family proteins as effectors and there are also 
intracellular regulators of these cell death programs, most importantly, Bcl-2 protein 
family members. 
 
 
1.5.1.1 Caspases 
 
The caspases are a group of enzymes known as cysteine proteases. They are the 
main executors of the apoptotic process. In the normal conditions they exist within the 
cell as inactive pro-forms, but upon apoptosis induction procaspases get cleaved to 
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bring out the active enzymes. Their active forms mediate apoptosis by an intracellular 
proteolytic cascade, cleaving several key proteins in the cell one by one so that the cell 
start to break down(88, 91).  
Caspases divide into two classes: initiator caspases include procaspases 2, 8, 9, 
10 while the executioner caspases consist of procaspases 3, 6 ,7. Initiator caspases are 
the ones that get activated first, then they cleave the executioner caspases to further 
promote apoptotic signaling(92).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.5.1.2 Bcl-2 protein family 
 
As the intracellular regulators of apoptosis, Bcl-2 protein family has always been 
approached with great interest. Having several members with different critical roles 
make this protein family an indespensable study in the understanding of apoptotic 
mechanisms. The family divides into two groups considering their contribution to 
Figure 1. 9 Pathways of Apoptosis: Effector Caspases and Regulator Bcl-2 Family 
Members. 
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apoptosis: they are either antiapoptotic or proapoptotic. The antiapoptotic members are 
Bcl-2, Bcl-XL and Mcl-1, whereas  Bax, Bak and Bok belong to the proapoptotic group 
along with Bid, Bim, Bad, Noxa, Puma and several others up to 30 known relatives(93, 
94). 
There are hundreds and thousands of articles on the members of Bcl-2 protein 
family, examining their roles and how they affect apoptotic signaling pathways alone or 
working together. They achieve their regulatory roles by controlling caspase activation 
and maintain mitochondrial integrity(95, 96). Proapoptotic members mostly rely on 
either (like Bad) binding to and inactivating antiapoptotic ones(97, 98) or (like Bax and 
Bak) by provoking the permeabilization of mitochondrial membrane and stimulating the 
cytochrome c release(99). Bid is another proapoptotic member of this family taking 
charge in between extrinsic and intrinsic pathways and it causes their overlapping as it 
gets truncated by caspase 8, translocates to the mitochondria and helps Bax/Bak for 
mitochondrial membrane permeabilization(94).  
The prosurvival members Bcl-2, Bcl-XL and Mcl-1 inhibit apoptosis by 
blocking the release of apoptotic proteins from the mitochondria(100, 101). However, it 
is Mcl-1 having interesting features that outshine other antiapoptotic members, making 
it ‘an essential survival protein’ among them(102). Most importantly, it is capable of 
being induced upon proliferation and differentiation and it shares structural properties 
with some crucial cell cycle proteins such as cyclin D1, E, G2 and c-Fos unlike other 
Bcl-2 proteins. With these special attributes, Mcl-1 is able to regulate both apoptosis 
and cell cycle progression(103).  
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2. PURPOSE 
 
 
 Cancer is a class of diseases characterized by abnormal cell growth and division. 
It is a leading cause of death and according to World Health Organization it caused 7.6 
million deaths in 2008 stating that it accounted for around 13% of all deaths(104).  
Colon cancer is among the most commonly diagnosed cancers. We selected 
colon carcinoma cell lines HCT 116 WT, p53 -/- and Bax -/- for this study. For the 
effectively killing of these colon cancer cells, we aim to target their glycolytic 
metabolism and couple glycolysis inhibition to cisplatin and Killer TRAIL treatment. 
Our purpose is to sensitize the cells to apoptosis induced by these agents and potentiate 
their effects on colon cancer cells. Also we want to provide a mechanistic understanding 
of this sensitization effect: how it happens, which pathways it activates, what changes 
does it cause at protein and gene level, how does it affect apoptotic signaling, cell 
growth and proliferation signals and so on. 
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3. MATERIALS 
 
 
3.1 Chemicals 
 
 Chemicals used are listed in Appendix A. 
 
3.2 Antibodies 
 
 Antibodies used are listed in Appendix B. 
 
3.3 Molecular Biology Kits and Cell Culture Materials 
 
 Molecular biology kits which are used for determination of cell proliferation, 
measurement of ATP levels, immunoblotting experiments, plasmid isolation and gene 
transfection are listed in Appendix C. Appendix C also includes specialty materials such 
as the used protein marker and plasmid. 
 
3.4 Equipment 
 
 Equipment used for general procedures in the laboratory is listed in Appendix E. 
 
3.5 Buffers and Solutions 
 
 
3.5.1 Buffers and Solutions for FACS Analysis 
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Annexin V-FITC incubation buffer: 10 mM Hepes, 140 mM NaCl and      2.5 
mM CaCl2  were dissolved in 500 ml of ddH2 O. The buffer is stored at 4°C. 
 
 
3.5.2 Buffers and Solutions for Total Protein Isolation 
 
Cell Lysis Buffer: 150 mM NaCl, 1% NP-40 and 50 mM Tris dissolved in 
ddH2 O; afterwards pH is adjusted to 8.0 by using 5M HCl solution. The buffer was 
stored at 40C.  
 
Complete cell lysis buffer: Prior to protein isolation, complete lysis buffer is 
prepared by adding 1X protease inhibitors, 1X phosphatase inhibitors and 0.5 M PMSF 
freshly to cell lysis buffer.  
 
10X PBS (Phosphate Buffered Saline): 80 g NaCl, 2.0 g KCl, 14.4 g Na2- 
HPO4 and 2.4 g KH2PO4 were dissolved in 1L of ddH2O and pH is adjusted to 7.4. 
 
 
3.5.3 Buffers and Solutions for SDS polyacrylamide gel electrophoresis 
 
1.5 M Tris-HCl pH 8.8: 1.5 M Tris was dissolved in ddH2O and pH was 
adjusted at 8.8 with HCl.  
 
0.5M Tris-HCl pH 6.8: 0.5M Tris was dissolved in ddH2O and pH was 
adjusted at 6.8 with HCl. 
 
 
3.5.4 Buffers and Solutions for Western Blotting 
 
10X Running Buffer: 30.3 g Tris, 144.1 g Glycine, 10 g SDS were dissolved in 
1L of ddH2O and pH was adjusted at 8.3.  
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10X Transfer Buffer (TB): 30.3 g Tris and 144 g Glycine were dissolved in 1L 
of ddH2O.  
 
1X Transfer Buffer: Before conducting transfer step, 1X TB is freshly 
prepared. 20% (v/v) methanol was added into 1X TB and the remaining volume was 
completed with ddH2O.  
 
10X PBS (Phosphate Buffered Saline): 80 g NaCl, 2.0 g KCl, 14.4 g 
Na2HPO4 and 2.4 g KH2PO4 were dissolved in 1L of ddH2O and pH is adjusted to 7.4. 
 
1X PBS-Tween20 (PBS-T): 10X PBS was diluted to 1X, 0.2% Tween20 was 
added to 1X PBS. 
 
Blocking Solution: 0.05% (w/v) dried milk powder was dissolved in 1X PBS-T. 
 
 
3.5.5 Buffers and Solutions for Cell Cycle Analysis 
 
PI  incubation buffer: 2 ml PBS and 12 μl TritonX100 were mixed. For ten 
samples, 1 ml was taken to which 10 μl RNase and 20 μl PI solution were added. The 
mixture is distributed equally (~100 μl to each) to the samples before incubation. No 
dye sample only has RNase in the incubation buffer.  
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4. METHODS 
 
 
4.1 Cell Culture 
 
HCT116 WT, p53 -/- and Bax -/- cells were cultured in McCoy’s 5A Modified 
Medium (Modified) with L-glutamine added with %10 fetal bovine serum (FBS) and 
1% penicillin/streptomycin (100 U/ml). Cultures were kept in the incubator at 37°C and 
5% CO2. T-75 flasks, 6-well culture plates, 12-well culture plates and 96-well plates 
were used for the seeding of the cells. Cell splitting by trypsin was done after the cells’ 
reaching to a considerable confluency (~80%). Cells are counted with hemacytometer 
according to the following formula: 
 
 
 
And the split cells were passaged to culture plates and flasks, taking the appropraite 
seeding densities(Table 4.1) of each into account. 
 
 
Figure 4. 1 Cell Seeding Density for Culture Plates and Flasks 
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For cryopreservation, cells were trypsinized and resuspended in complete 
medium containing 10% heat-inactivated FBS and 10% DMSO. The cell suspension in 
freezing medium was transferred into cryovials, frozen at -80 º C for 24 hours, and then 
stored in liquid nitrogen to remain until thawing. 
 
 
4.2 Cell Death Analysis 
 
Cells were seeded in 12-well culture plates considering the appropriate cell 
seeding numbers for flow cytometry analysis. After 24h of incubation, cells were 
attached to surface and they were ready for cisplatin and Killer TRAIL treatments. The 
dose dependence check for cisplatin treatment included the concentrations 0.1, 4, 8, 16, 
32 μM, then we decided on the concentrations 20 μM and 30 μM for further 
experiments. For Killer TRAIL treatment we selected the concentration 100ng/ml. After 
the treatments, cells were harvested at 24 and 48 hours through trypsinization and 
washed twice with cold 1X PBS. The cells were centrifuged at 300g for 5 min, then the 
supernatant was discarded and the pellet was resuspended in 100μl 1X Annexin-V 
binding buffer then cell suspension was incubated with 2μl of FITC-conjugated 
Annexin V (Pharmingen) for 15 min at room temperature in the dark. 500 μl of 1X 
Annexin-V binding buffer was added to each sample tube, and the samples were 
analyzed by FACS (Becton Dickinson) using FACS BD software. 
For the potentiation of anticancer agents cisplatin and Killer TRAIL, glycolytic 
inhibitor 2-Deoxyglucose(2-DG) (Sigma) pretreatment was done. After the seeding and 
incubation steps, cells were treated with 10mM 2-DG for 24 hours. Next day, the 
medium wass discarded and renewed and cisplatin/Killer TRAIL treatments started. The 
next steps were followed as stated in the first paragraph. 
 
 
4.3 Total Protein Isolation 
 
HCT 116 cell lines WT, p53 -/- and Bax -/-  were harvested for protein analysis 
having control and various treatment samples. They were washed in ice cold PBS and 
lysed on ice in 200 μl complete lysis buffer containing freshly added 1 mM PMSF, 
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protease inhibitor cocktail (Roche, Mannheim, Germany) and phosphatase inhibitors 
(Roche, Mannheim, Germany). It took 30 minutes on ice for the proper lysis of the 
cells, cell debris was removed by cold centrifugation (4°C) for 10 min at 13200 rpm. 
Supernatant containing the total protein extracts are transferred into eppendorf tubes and 
they were immediately put in storage at -80°C. Protein concentrations were determined 
with Bradford Protein assay. 
 
 
4.4 Determining Protein Concentrations 
 
Protein concentrations were determined with Bradford Protein assay. Bradford 
assay is a colorimetric protein assay that relies on the binding of the dye Coomassie 
Brilliant Blue G-250 to protein, giving out a blue color. Concentration measurement is 
based on this absorbance shift of the dye. The procedure we carried out is as follows: 
1μl of protein sample was diluted with 4 μl distilled water in 95 μl of 1X Bradford 
reagent. With serial dilutions of BSA as 5, 2.5, 1.25, 0.625, 0.313 μg, we obtained a 
standart curve. By dividing the obtained optical density at 595 nm (OD595) to the slope 
of the standart curve, the protein concentration was calculated in μg/μl. 
 
 
4.5 SDS-PAGE Gel Electrophoresis 
 
 The purpose of SDS-PAGE is to separate proteins according to their size. It is 
the most widely used technique for analyzing mixtures of proteins. The anionic 
detergent sodium dodecylsulfate (SDS) denatures all proteins to the same linear shape 
coating them with negative charges as it binds to the hydrophobic side chains of 
proteins and breaks non-covalent interactions. As the proteins are put into an electric 
field they move towards the positive pole through the polyacrylamide gel moving at 
different rates according to their size. 
The overall procedure starts with the pouring of the gel. It consists of two parts, 
a stacking gel laying on top of a separation gel. As the proteins are passing from the 
stacking to the separating gel, they are confined to a narrow band due to the different 
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pH values. Bio-Rad mini protean gel apparatus were used for the preaparations of the 
gel.  
Percentages of the separating gel can change according to the size of the proteins 
for better results. In our study, 12% separating gel was convenient for the proteins we 
checked out. Here are ingredients: for two gels in 1mm glasses 3.4ml distilled water, 
2.5ml pH 8.8 1.5M Tris-HCl, 50μl 20% (w/v) SDS, 4ml 30% Acrylamide/ 0.8 bis-
Acrylamide solution, 50 μl 10% APS and 5 μl TEMED in the given order. After the 
casting of the gel between the glasses, isopropanol was poured upon to prevent contact 
with oxygen and to eliminate bubbles. In about 40 minutes gel was ready, polymerized, 
we got rid of the isopropanol and stacking gel iwas prepared and casted: again for two 
gels in 1mm glasses 3.075ml distilled water, 1.25ml 0.5M Tris-HCl, 25μl 20% (w/v) 
SDS, 670 μl 30% Acrylamide/ 0.8 bis-Acrylamide solution, 25 μl 10% APS and 5μl 
TEMED in the given order. Combs were placed in order to get wells inside the gel. As 
the polymerization finished, the prepared protein samples(with loading dye) were 
loaded inside the wells along with a protein marker (Fermentas, Germany) and the gel 
was ready to run. In our condition, SDS-PAGE was run for one and a half hours at room 
temperature with a constant voltage of 100V. 
 
 
4.6 Western Blotting Procedure 
 
 After the separation of the proteins on 12% SDS-PAGE, they were blotted onto 
PVDF membranes. The membranes were then blocked with blocking solution, 5% dried 
milk in PBS-Tween20, and incubated with appropriate primary and secondary 
antibodies(listed in Appendix B) diluted respectively to 1/2000 (v/v) and 1/5000 (v/v) in 
blocking solution. After the washes with PBS-Tween 20, detection of blots were 
performed by an enhanced chemiluminescence detecton system and the results were 
exposed to Hyperfilm-ECL. 
 
 
4.7 Cell Cycle Analysis 
 
 Flowcytometric cell cycle analysis is a well-working method for the assessment  
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of cell cycle distribution. In this study, HCT 116 WT,   p53-/- and Bax -/- cell cycle 
distribution were checked after 10mM 2-DG treatment for 24h via PI staining using 
flowcytometer.  
 The cells were seeded in 12-well plates in appropriate seeding densities. They 
were incubated at 37°C and 5% CO2 for 24h in order to make them attach onto the 
surface. Next day, the treatment took place. 24 hours later, they were detached by 
trypsinization and washed with cold 1X PBS. Following the centrifugation for 5 
minutes at 300g, the supernatant was discarded and the pellet was vortexed gently. We 
then added 5 ml 70% Ethanol into the tubes for fixation. At this step, the cells can be 
stored up to 4 weeks at 4°C in ethanol. After at least 2 hours of wait, the cells were 
ready for spin down (5 minutes at 300g), and another cold 1X PBS wash done, then 
another spin down. The supernatant was discarded and 100 μl PI solution was added to 
cells and we kept them in a dark storage for 45 minutes at room temperature. 500 μl of 
PBS was added to stop the reaction and they were ready for the FACS analysis. 
 
 
4.8 Proliferation Assay 
 
 To confirm the antiproliferative effects of the anticancer agents, we performed 
proliferation assay by using CyQUANT Proliferation Assay Kit. We followed the 
procedure according to the given protocol. The cells were seeded in black microplates 
and after appropriate treatments they were given dye in lysis buffer. The fluorescence 
was measured by spectrofluorometer. 
 
 
4.9 Transfection Procedure 
 
 Mcl-1 overexpression plasmid pCMV-Flag-hMcl-1 were bought from addgene. 
pCMV vector was used for mock transfections. The transient plasmid DNA transfection 
was done with the following procedure: HCT 116 WT, p53 -/- and Bax -/- cells were 
seeded in 12-well plates and transfected with the plasmid (1μg) using X-tremeGENE 9 
DNA transfection reagent according to the manufacturer’s protocol. The transfection 
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medium was removed next day and further treatments continued afterwards. The 
transfection efficiency was monitored via western blotting analysis. 
 
 
4.10 RNA Isolation 
 
 RNAs from 2-DG treated HCT 116 WT and p53 -/- cells were isolated following 
this procedure: The cells had been seeded and treated in 6-well plates. After the 
treatment, medium was discarded and the cells were washed with cold 1X PBS. 500 μl 
TRIZOL was added and the cells started to detach from the surface. TRIZOL disrupts 
and breaks down the cells while maintaining RNA integrity. 5 minutes of wait at room 
temperature. Then, 100 μl Chloroform was added. We inverted the tubes 10 times after 
chloroform addition. Another 2-3 minutes of wait. The tubes were centrifuged at 12000 
rcf for 15 minutes at 4°C. Three phases formed in the tubes as RNAs being in the upper 
phase. The upper phase was taken into a new tube and 250 μl of isopropanol was added. 
Tubes were inverted 10 times, and we waited for 10 minutes leaving them at room 
temperature. Another centrifugation step followed with the same condition as the 
previous one. The supernatant was discarded, 500 μl 80% EtOH was added, and the 
tubes were vortexed. The cells then underwent another centrifugation step, this time at 
7500 rcf for 5 minutes at 4°C. The supernatant was discarded, we let the tubes dry for 
10 minutes, to eliminate alcohol. After that, the RNA pellet was dissolved in 50 μl 
dH2O-DEPC, the concentrations were checked via Nanodrop and they were ready for 
storage at -80°C. 
 
 
4.11 Microarray 
 
 In the field of molecular biology, microarray technology provides crucial 
insights for the understanding of cellular function by measuring the expression levels of 
thousands of genes. In our study, we planned on to look for the change of gene 
expression levels of the colon cancer cell lines by examining the activity of the 
identified target genes of cancer pathways, metabolic pathways and apoptosis pathways.  
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Isolated RNAs from HCT 116 WT and p53 -/- cells with control and 2-DG 
treatment conditions sent to Dr. Pieter Faber from USA Cleveland Clinic, Genomic 
Medicine Institute. The RNAs were processed into cRNAs there, hybridized to arrays 
and scanned on Illumina BeadArray reader. The results were taken from Illumina's 
BeadStudio software which produced data files in excel-format. We wanted whole-
genome gene expression analysis, and Illumina’s gene expression arrays provided the 
most up-to-date expression content and high-throughput processing, promising the 
production of high-quality data for large gene expression studies, efficiently and 
economically. We selected the HumanHT-12 v4 Expression BeadChip for 
more biologically meaningful results through genome-wide transcriptional coverage of 
well-characterized genes, gene candidates, and splice variants. 
 
 
4.12 Statistical Analysis of Cell Death Graphics 
 
 The results are expressed as mean ± SEM and the mean values were compared 
using Students t-tail test. Values of P<0.05 and P<0.01 were considered statistically 
significant. 
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5. RESULTS 
 
 
5.1 Results 
 
 
5.1.1  Assessment of Apoptosis Induction Profile of Cisplatin and Killer TRAIL as 
selected anticancer agents: 
 
Cisplatin and Killer TRAIL were selected as apoptosis inducers in this 
anticancer treatment. We did a literature reseach on Killer TRAIL’s dose- and time- 
dependence. What we got out of this research is that the product data sheet suggests 
Killer TRAIL’s induction of apoptosis in a concentration range of 10-100ng/ml. We 
have seen two different articles selecting doses 100ng/ml and 200ng/ml(82, 83). We 
decided on starting with 100ng/ml and going along with what the results would provide 
us. On the other hand, we wanted to do dose- and time- dependence experiments for 
cisplatin’s induction of apoptosis, to decide on the concentration values for further 
experimental analysis. 
The initial results for cisplatin concentrations varied in terms of apoptosis 
induction. HCT 116 p53 -/- cells were expectedly resistant in comparison to HCT 116 
WT cells. But after 24 hours, we couldn’t get sufficient cell death response up to 16μM 
cisplatin(FIG. 5.1). 32μM of cisplatin caused over 25% cell death for WT cells and near 
15% for p53 -/- cell. This would be good enough for further studies. Still, as the 48-hour 
cell death analysis provided better and cleaner results, and 32μM this time causing up to 
35% of cell death for WT cells and near 25% for p53 -/- cells made us select 48 hours as 
our time condition. For the dose, we chose 20μM and 32μM of cisplatin concentrations. 
The point of selecting 20μM was to stretch out the cell death percetage a little more than 
what 16μM has given us. 
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We also analyzed cell death after Killer TRAIL treatment, but in this set we had 
HCT 116 WT and Bax -/- cells. HCT 116 Bax -/- cells were highly resistant to Killer 
TRAIL, so they showed very little or no apoptosis induction, unlike WT cells. 100ng/ml 
of Killer TRAIL resulted in around 16% cell death in HCT 116 WT cells for both 24 
and 48-hour conditions(FIG. 5.2). We selected to go for 48-hour treatment for the next 
experiments. 
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Figure 5. 1 
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Figure 5.1 Apoptosis induction analysis of HCT116 WT and p53 -/- cells treated with 
increasing concentrations of cisplatin for 24 and 48 hours. Cell death analysis was 
performed by Flow Cytometry – AnnexinV  labeling. A-The graphs show the mean 
percentage of cell death in the control cells and the drug treated cells. Data are shown as 
mean ± SEM representative of at leat two experiments. ** P < 0.01,  * P < 0.05 B- The 
histograms showing the shift in the intensity of fluorescence dye between control and 
32μM cisplatin  treated cells.  (Appendix D has the detailed flow-jo graphs of 
populations selected for analysis and the histograms showing the shift in the intensity of 
fluorescence dye between control and cisplatin treated cells.) 
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Figure 5. 2 Apoptosis induction analysis of HCT116 WT and Bax -/- cells treated with 
100ng/ml Killer TRAIL for 24 and 48 hours. Cell death analysis was performed by Flow 
Cytometry – AnnexinV  labeling. A- The graphs show the mean percentage of cell death in 
the control cells and the drug treated cells. Data are shown as mean ± SEM representative of 
at least two experiments.     ** P < 0.01,  * P < 0.05 B- The histograms showing the shift in 
the intensity of fluorescence dye between control and 100ng/ml Killer TRAIL  treated cells.  
(Check Appendix D for whole data) 
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5.1.2  Sensitization of HCT 116 WT, p53 -/- and Bax -/- cell lines to Cisplatin and 
Killer TRAIL-induced apoptosis by 2-DG Pretreatment: 
 
 In dose- and time- dependence experiments on anticancer agents, our aim was to 
select a concentration that showed induction of apoptosis to an extent not so high not so 
low. Because in the next step it gave us the opportunity to clearly detect the potentiation 
of these anticancer agents when treated after the cells’ pretreatment with 2-DG, a 
glycolytic inhibitor. 
 First HCT 116 WT and p53 -/- cells underwent 10mM 2-DG pretreatment for 24 
hours. Then they were given cisplatin on several concentration levels for 48 hours. 
Potentiation of cisplatin by 2-DG pretreatment showed itself in 20 and 32 μM cisplatin 
concentration samples: Cell death percentages for WT sample rising around 10% and 
for p53 -/- sample around 13% (FIG. 5.3). The results were more than satisfying 
considering that 2-DG pretreatment clearly increased cell death percentages. 
 The other set was also ready to taste 2-DG before Killer TRAIL treatment. They 
were given 10mM 2-DG and the pretreatment lasted 24 hour long, exactly the same 
condition as the first set. Then Killer TRAIL treatment followed for 48 hours. This 
started off exciting because we had HCT 116 Bax -/- cells in this study set along with 
HCT 116 WT. And Bax -/- cells were highly resistant to Killer TRAIL-induced 
apoptosis. We were about to see whether or not 2-DG could sensitize Bax -/- cells and 
make them respond to the treatment by inducing apoptosis.  
 It came out, however, rather disappointing because nothing changed for Bax -/- 
cells as they were perfectly well. WT cells, on the other hand, showed increase in cell 
death. Apoptosis induction rose up 10% when Killer TRAIL was given to cells after 2-
DG pretreatment(FIG. 5.4). 
 These results suggest that 2-DG can potentiate selected anticancer agents and 
increase cell death numbers by sensitizing the cells. 
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Figure 5. 3 
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Figure 5.3 Sensitization of HCT116 WT and p53 -/- cells to cisplatin induced 
apoptosis. Cell death analysis was performed by Flow Cytometry – AnnexinV  labeling. 
A- The graphs show the mean percentage of cell death in the control cells and the drug 
treated cells. Data are shown as mean ± SEM representative of at least two experiments. 
** P < 0.01,  * P < 0.05 B- The histograms showing the shift in the intensity of 
fluorescence dye between control, Cisplatin, 2-DG + Cisplatin samples. (Check 
Appendix D for whole data) 
 
 
 
 
Figure 5. 4 Sensitization of HCT116 WT and Bax -/- cells to Killer TRAIL induced 
apoptosis. Cell death analysis was performed by Flow Cytometry – AnnexinV  labeling.     
A- The graphs show the mean percentage of cell death in the control cells and the drug 
treated cells. Data are shown as mean ± SEM representative of at least two experiments. ** P 
< 0.01,  * P < 0.05 B- The histograms showing the shift in the intensity of fluorescence dye 
between control, Killer TRAIL, 2-DG + Killer TRAIL samples.  (Check Appendix D for 
whole data) 
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5.1.3  Checking antiproliferative properties of Cisplatin by Proliferation Assay 
 
 To further confirm the decrease in cell number, we performed proliferation assay 
for the first set, being HCT 116 WT and p53 -/- as the cell lines and cisplatin as the 
anticancer agent. We didn’t perform this for the second set because we couldn’t achieve 
Bax -/- sensitization and so performing the assay would be rather redundant. 
 The results gave countenance to the FACS analyses. Checking DNA content by 
this proliferation assay, 20μM Ciplatin treatment was selected as representative. And 
the results showed that when treated after 2-DG pretreatment, cisplatin gained a lot in 
terms of its antiproliferative properties causing further decrease in cell numbers. 
 
 
 
5.1.4  Sensitization of HCT 116 Bax -/- Cells to Killer TRAIL-induced apoptosis 
 
As the initial results came off unsuccessful when we tried sensitizing HCT 116 
Bax    -/- cells by 2-DG pretreatment to Killer TRAIL-induced cell death, we looked for 
other possible ways as to how we could do it. We had two other compounds that target 
Figure 5. 5 Proliferation Assay results after HCT 116 WT and p53 -/- cells’ treatment 
with Cisplatin and 2-DG. 2-DG pretreatment for 24 h prior to 48 h treatment of 20μM 
Cisplatin. Analysis was done on spectrofluorometer as the absorbances were measured. 
The graphs show the mean percentage of cell proliferation in the control cells and the 
drug treated cells. Data are shown as mean ± SEM representative of at least two 
experiments. 
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potential survival mechanisms that might help Bax -/- cells to resist against cell death 
signaling. 
One of them was the BH3 mimetic, Abt-737, targeting Bcl-2 and Bcl-XL, two of 
the most important antiapoptotic Bcl-2 protein family members. The aim was to inhibit 
these antiapoptotic cell death regulators and therefore sensitize the cells if these proteins 
were really that important for Killer TRAIL induced apoptosis. But, as the results 
suggested, Abt-737 treatment couldn’t work as we expected with no significant changes 
between 2-DG + Killer TRAIL and 2-DG + Abt-737 + Killer TRAIL sample (FIG. 5.6). 
 
 
As you may already seen by looking at figure 6, 3-Methyladenine (3-MA) was 
the other promising compound that ended up disappointing for our purposes. 3-MA is 
widely used as autophagy inhibitor. We thought autophagic cell survival might be 
responsible for this high resistance among Bax -/- cells. However, the results were 
confusing on this front, because we never thought 3-MA would increase cell death 
when treated alone. And 5mM was a widely used concentration level for this 
compound. This might mean two things: one is that this concentration was somehow 
Figure 5. 6 Sensitization of HCT116 Bax -/- to Killer TRAIL-induced apoptosis. 
Treatment of HCT 116 Bax -/- cells with 400nM Abt-737 and  5mM 3-MA for 48h 
alone and concurrently with 100ng/ml Killer TRAIL after 2-DG pretreatment. Cell 
death analysis was performed by Flow Cytometry – AnnexinV  labeling. The graphs 
show the mean percentage of cell death in the control cells and the drug treated 
cells. Data are shown as mean ± SEM representative of at least two experiments.  ** 
P < 0.01,  * P < 0.05 (Check Appendix D for whole flow jo data) 
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toxic to HCT 116 Bax -/- cells; two 48 hour long treatment caused some kind of an 
increase in autophagic flux resulting in autophagic cell death. However, both of these 
remarks went nowhere for our study considering that 3-MA treatment didn’t help for 
potentiation of Killer TRAIL induced apoptosis when treated concurrently. 
So both Abt-737 and 3-MA treatments couldn’t sensitize Bax -/- cells, but was it 
due to not getting a proper induction of cell death because of their resistance? We 
checked their effect on HCT 116 WT cells to see what would happen when there was a 
proper apoptotic signaling (FIG. 5.7). 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 These results confirmed their inability to potentiate Killer TRAIL induced 
apoptosis, because as you can see 3-MA caused 15% cell death when given alone and 
when it’s given concurrently with Killer TRAIL the cell death percentage(~14%) didn’t 
change. However, when it’s given along with Killer TRAIL after 2-DG pretreatment the 
cell death percentage went higher in comparison to Figure 5.4’s 2-DG + Killer TRAIL 
Figure 5. 7 Abt-737 and 3-MA effects on HCT 116 WT cells. Cell death 
analysis was performed by Flow Cytometry – AnnexinV  labeling. The 
graphs show the mean percentage of cell death in the control cells and the 
drug treated cells. Data are shown as mean ± SEM representative of at least 
two experiments. ** P < 0.01,  * P < 0.05 (Check Appendix D for whole 
flow jo data) 
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sample. This might be a slight sensitization effect. But still it didn’t help for anything, 
as it couldn’t overcome Bax -/- cells’ resistance. 
 Abt-737 treatment gave almost identical results as Figure 5.4, like it was not 
there at all. The percentages matched with control, Killer TRAIL and 2-DG + Killer 
TRAIL samples from figure 5.4. Nothing suggested a further potentiation of Killer 
TRAIL or sensitization of HCT 116 WT and Bax -/- cells. 
 
 
5.1.5  Apoptotic Effects of Cisplatin and Killer TRAIL: Immunoblot Analysis 
 
 The anticancer agents cisplatin and killer TRAIL cause cell death by inducing 
apoptosis. After the intial flowcytometic analysis of HCT 116 cell lines following the 
treatments, Annexin V staining gave us the first impressions of apoptosis induction. The 
next step was to detect it on protein level by checking caspases, because caspase 
cleavage is the signature event of apoptotic signaling. 
 Caspase 3 and caspase 8 were checked for the first set, both HCT 116 WT and 
p53 -/- cells showed caspase 3 cleavage confirming the apoptotic response. Caspase 8 
was not cleaved in this set (FIG. 5.8). And that was quite plausible considering that 
caspase 8 is important for extrinsic apoptotic pathway, getting cleaved by intracellular 
parts of death receptors. One thing we expected here was that the increase in cell death 
numbers could relate to increased caspase cleavage when cisplatin was given after 2-
DG pretreatment. But cleaved caspase 3 western blot didn’t come out that way. Even 
showing a slight decrease. However, this might be interpreted in a different way as that 
level of caspase 3 cleavage could be enough for an improved apoptotic response in 
sensitized cells. 
We checked caspase 8 for the Killer TRAIL set and only for HCT 116 WT cells 
because Killer TRAIL couldn’t induce an apoptotic response in HCT 116 Bax -/- cells. 
All cleaved products were clearly there in this immunoblot and this time we could even 
see a slight increase in cleaved caspase 8 products. However, interestingly, full lenght 
caspase 8 was also increased in 2-DG+Killer TRAIL sample.  
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Figure 5. 8 Western Blot Analysis of Caspases and BID. Western Blot Analysis of HCT 116 
WT, p53 -/- and Bax -/- cells following their treatment with 2-DG(10mM, 24h pretreatment) 
and Cisplatin||Killer TRAIL(20μM, 48h||100ng/ml, 48h). Total cytosolic proteins isolated, 
caspase protein levels were detected with antibodies. β- actin was used as loading control. 
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BID was another protein checked for this set. It is an important proapoptotic 
Bcl-2 family member overlapping the intrinsic and extrinsic pathways of apoptosis. The 
crucial feature is that it gets truncated by caspase 8. WT samples showed the decrease in 
BID protein levels and finally vanishing in killer TRAIL and 2-DG+Killer TRAIL 
samples, while Bax -/- cells expectedly did not. 
The western blot results spotted effector caspases in action and so confirmed that 
our selected anticancer agents kill cancer cells by inducing apoptosis. 
 
5.1.6  Role of Some Bcl-2 Protein Family Members in Sensitization of the Cells and 
Potentiation of Apoptotic Signaling 
 
Bcl-2 protein family are crucial regulators of apoptotic signaling. Building the 
family upon two distinct classes named anti- and pro- apoptotic means so much in terms 
of their regulatory contributions. Therefore, after checking apoptosis markers in the 
previous western blotting experiments, we leaned over Bcl-2 protein family and looked 
for the changes on protein levels after 2-DG treatment. All three cell lines, HCT 116 
WT, p53 -/- and Bax -/- provided samples for this study as they were treated with 
10mM 2-DG for 24h. Our aim was to detect any meaningful change that might help us 
for the understanding of potentiation of apoptosis induction caused by cisplatin and 
Killer TRAIL. 
First we checked antiapoptotic members of the family, being Bcl-2 and Mcl-1. 
While Bcl-2 protein levels didn’t change, decrease of Mcl-1 protein levels in all cell 
lines (obviously in WT and Bax -/-, slightly in p53 -/-)  after 2-DG treatment gave us a 
crucial result(FIG. 5.9). Being a highly important antiapoptotic protein regulating the 
apoptotic signaling in a preventive manner, Mcl-1’s decreased protein levels means a hit 
out of the park in the name of getting the first clue to how 2-DG sensitizes the cells.  
The next step was to check some of the proapoptotic members of the family, 
mostly the ones that have a connection to Mcl-1. However, the protein levels of both 
Bax and Bim didn’t change(FIG. 5.9).  
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5.1.7  Assessment of ATP Levels: 2-DG and Energy Metabolism 
 
 To look at the event from a different perspective, finally in the light of the 
Warburg effect we measured ATP levels after the cells’ treatment with 10mM 2-DG. 
Our expectation was to detect a difference after 24h treatment. However, the cells 
showed little or no decrease in ATP levels after that time period. We then changed the 
treatment time to 5h in order to see an early response from the cells and the plan served 
our purpose by giving us a result of around 20% decrease in ATP levels of all three cell 
lines(FIG. 5.10 A). 
Figure 5. 9 Western Blot Analysis of Bcl-2 Portein Family. Western Blot 
Analysis of HCT 116 WT, p53 -/- and Bax -/- cells following their 
treatment with 2-DG (10mM, 24h). Total cytosolic proteins isolated, Bcl-
2 family protein levels were detected with antibodies. β- actin was used 
as loading control. 
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 To further confirm the ATP decrease, we checked the levels of phoshorylated 
AMPK alpha. AMPK is a conserved enzyme working as an energy sensor. When ATP 
levels decrease, it gets activated via phosphorylation and signals for energy need to 
activate energy generating pathways. We checked for the protein levels of its 
phoshorylated form after 5 hours of 10mM 2-DG treatment. And the results confirmed 
the decrease in ATP levels as all three cell lines showed AMPK activation(FIG. 5.10 B). 
The decrease in ATP levels after 2-DG treatment may very well be one of the effective 
mechanisms of 2-DG’s ssensitization effect over HCT 116 cell lines. 
 
 
 
5.1.8  Regulation of mTOR Pathway 
 
 AMPK activation is shown to affect mTOR activity(36, 79).Therefore, with the 
increase in activation of AMPK, we wanted to look at one of the significant cancer 
Figure 5. 10 2-DG treatment effects on cellular ATP levels. A- ATP levels measured in 
HCT 116 WT, p53 -/- and Bax -/- cell lines after 10mM 2-DG treatment for 5h and 24h. 
Data are shown as mean ± SEM representative of at least two experiments. ** P < 0.01,  
* P < 0.05 B- Total cytosolic proteins isolated from all three cell lines after 10mM 2-
DG treatment for 5 hours. Phospho-AMPK protein levels were determined by western 
blotting. β- actin was used as loading control. 
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related pathways, mTOR signaling. mTOR is a highly important protein kinase having 
regulatory roles in cell growth, proliferation and survival as well as protein synthesis. 
To assess mTOR activity and in order to do it in a clear way, we checked the levels of 
the phosphorylated form of p70 S6 kinase, which is a downstream protein kinase 
working as translation regulator and it is the main target of mTOR. Hence, a potential 
change in mTOR’s activity would reflect itself upon the activation levels of p70 S6 
kinase. The results suggested so as phospho-p70 S6 kinase protein levels were 
decreased after 10mM 2-DG treatment for 24h(FIG. 5.11). We can say that 2-DG has an 
inhibitory effect on mTOR and thereby it opens a giant pool of various possibilities as 
to how mTOR inhibition serve for the cell’s sensitization considering its roles in 
growth, proliferation, protein synthesis and so on. 
 
 
 
 
 
 
 
 
 
 
 
 
5.1.9  Effect of 2-DG Treatment on Cell Cycle Distribution 
 
 Performing cell cycle analysis was an idea thrown out for the consideration of 
another possible sensitization mechanism. We wanted to show if 2-DG would cause a 
difference in cell cycle distribution, maybe even cell cycle arrest in comparison to 
control samples. And with the results, we found out that 2-DG caused cell cycle arrest at 
G1 phase, bringing down the cell numbers of S and G2 phase(FIG: 5.12 A). It is the 
Figure 5. 11 Western Blot Analysis of Phospho-p70 S6K. Western Blot 
Analysis of HCT 116 WT, p53 -/- and Bax -/- cells following their treatment 
with 2-DG (10mM, 24h). Total cytosolic proteins isolated, phospho-p70 S6 
kinase protein levels were detected. β- actin was used as loading control. 
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point where a cell decides between dividing and resting. Apparently 2-DG treatment 
prevented cells from going into the phase of synthesis. 
 For this matter, p53 protein levels were detected by western blotting because of 
it’s utmost importance as a cell cycle regulator among its many other specifications. 2-
DG caused a decrease in p53 protein levels(FIG: 5.12 B), giving us another interesting 
result to discuss and interpret as p53 signaling has connection to cell cycle, Mcl-1, 
AMPK and mTOR. 
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5.1.10  Finding out Mcl-1’s Importance: Mcl-1 Overexpression and Apoptosis 
Induction 
 
 In order to place further emphasis on Mcl-1 and to label it ‘critical’ for this 
study, we analyzed the effects of Mcl-1 overexpression. We studied it with the first set, 
HCT 116 WT and p53 -/- cell lines were transfected with the overexpresion plasmid, 
pCMV-Flag-hMcl-1. Following the transfection, after 24 hours of incubation, the cells 
underwent 10mM 2-DG pretreatment for 24 hours and then 20μM and 32μM cisplatin 
treatment took place for 48 hours. 
 Mcl-1 overexpression was highly effective in the name of its antiapoptotic 
properties, as cell death percentages went down at least 10% in each treated 
sample(FIG. 5.13 A). Even reducing the cell death numbers of 20μM cisplatin treated 
samples to the control levels. 
 Alongside flowcytometric analysis of apoptosis induction, western blotting 
results in Figure 5.13 B confirmed the overexpression of Mcl-1 protein. 
  
 
 
 
Figure 5. 12 Cell Cycle Analysis. A- Flowcytometric analysis of cell cycle 
distribution of HCT 116 WT, p53 -/- and Bax -/- cells following their treatment with 
2-DG (10mM, 24h). B- p53 protein levels were detected via western blotting. β- 
actin was used as loading control. 
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5.1.11  2-DG Effects on Gene Level: Microarray Study 
 
 In order to determine the identity of the genes that exhibit changes in their 
expression levels after 2-DG treatment, we went for microarray analysis. Isolated RNA 
samples from HCT 116 WT and p53 -/- cells (control and 10mM 2-DG treated -24h-) 
were sent as triplicates to Genomic Medicine Institute in Cleveland, where the analysis 
was done. We were informed at every level from the beginning with concentration 
checks and integrity tests. HumanHT-12 v4 Expression BeadChip was used as the 
Figure 5. 13 Overexpression of Mcl-1 in HCT 116 WT and p53 -/- cells to see its regulatory 
effect over cisplatin-induced apoptosis. Cell death analysis was performed by Flow 
Cytometry – AnnexinV labeling. A- The graphs show the mean percentage of cell death in 
the control cells and the drug treated cells. Data are shown as mean ± SEM representative of 
at least two experiments. ** P < 0.01,  * P < 0.05 (Check Appendix D for whole flow jo 
data) B- Confirmation of Mcl-1 overexpression in HCT 116 WT and p53 -/- cells by western 
blotting, protein isolation after transfection (48h). 
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RNAs were processed into cRNAs and hybridized to it. After the scanning on Illumina 
BeadArray reader, the results were taken from Illumina's BeadStudio software which 
produced data files in excel-format. 
 After a heavy work of analyzing the results, we selected 29 genes related to 
the study and divided them in four groups. The list was created with the following 
criteria: a p-value for differential gene expression of 0.05 or better and changes that 
happened in both WT and p53 -/- samples. 
 The results were interesting and very promising for the understanding of the 
effects of 2-DG on expression of genes that are related to cellular metabolism, 
apoptosis, cell cycle, cell growth, proliferation and tumorigenesis. It will also help for 
the future of this study in the name of selecting targets and determining signaling 
networks. 
 
5.1.11.1  Genes related to apoptosis 
 
TRIAP1 (aka p53CSV) gene expression was increased in both WT and p53 -/- 
samples after 2-DG treatment. Interestingly, this protein is stated as inhibitory to 
apoptosis and the gene is a target of p53. A study found that its induction happens when 
the cells have low levels of genotoxic stress but not when it is severe(105). Therefore 
we might say that 2-DG treatment alone causes a stress response in HCT 116 cells lines, 
and TRIAP1 expression increases. 
Caspase 2 and Caspase 3 are members of cysteine proteases and their sequential 
activation plays a central role in apoptosis. As the western blotting results didn’t show 
cleavage for caspase 3 after 2-DG treatment, its induction might mean some kind of a 
preparation for apoptosis. Unlike caspase 3, however, caspase 2 is not a well studied 
caspase and its role is not well defined. A recent article came up with an interesting 
analysis on its versatility, suggeting multiple functions in apoptosis, DNA repair and 
tumor suppresion(106). 
PDCD2, 5 and 6 are genes for programmed cell death proteins. PDCD2 is shown 
to induce apoptosis in human cells through activation of the caspase cascade(107). 
PDCD6 downregulation is associated with inhibition of apoptosis in ovarian cancer 
cells(108). PDCD5 is as well related to apoptosis induction. Its nuclear translocation is 
stated as an early and universal signal for apoptosis(109). Especially this protein held 
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our attention because there are some publications relating its low expression levels to 
downregulation of apoptosis(110, 111), and interestingly there are studies about its 
sensitization effects on cisplatin chemotherapy(112, 113, 114, 115). 
 
  
BCL-AF1 and BID belong to Bcl-2 protein family and these have regulatory 
roles in apoptosis  just like the other members. BID is a well known proapoptotic 
member that has enhancing effects over apoptosis. BCL-AF1 (aka BTF) is a relatively 
less known member. A 2010 dated review gave an overview of findings from past 
studies of this protein and they leaned over its role as an inducer of apoptosis and 
repressor of transcription(116). Also it has been shown to interact with other Bcl-2 
protein family members and its overexpression induces apoptosis(117). 
 
5.1.11.2  Genes related to cellular metabolism 
 
 LDHA codes for lactate dehydrogenase A enzyme. This enzyme is responsible 
for the conversion of pyruvate into lactate. The decrease in expression is probably the 
Figure 5. 14 Microarray Results: Expresion folds of the genes related to Apoptosis. 
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result of glycolysis inhibition upon 2-DG treatment, as you will see mot of the enzymes 
of the glycolytic pathway got downregulated. 
 COASY, coenzyme A synthase catalyze the last two steps in CoA synthesis. 
Coenzyme A derivatives play important roles in energy metabolism, especially Acetyl 
CoA. This enzyme gets in interaction with S6K(118) and so it might be another link 
between mTOR pathway and energy metabolism, apart from AMPK. 
 PDK3 code for an isozyme of pyruvate dehydrogenase kinase. It phosphorylates 
and inactivates pyruvate dehydrogenase complex which transform pyruvate into Acetyl-
CoA linking glycolysis to citric acid cycle. It is decreased in both WT and p53 -/- HCT 
116 cells. Interetingly it has been stated that the activation of pyruvate dehydrogenase 
complex(in this context, PDK downregulation helps for it) triggers apoptosis in cancer 
cells that selectively convert glucose to lactate(119). 
 
 
HK2 is the important enzyme here, as it interacts with 2-DG once it enters the 
cells. It commits glucose to the glycolytic pathway converting it to glucose 6-phosphate 
at the very beginning. HK2 gets downregulated after 2-DG treatment. One recent 
publication about its downregulation came up with the idea of a sensitization effect over 
cancer cells to chemotherapy(120). 
Figure 5. 15 Microarray Results: Expresion folds of the genes related to metabolism. 
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C12orf5 codes for TIGAR, TP53-induced glycolysis and apoptosis regulator. A 
detailed analysis over its functions suggested that its effects are cell and context 
dependent and it gets activated by low levels of stress(47). 
SCO2 is a mitochondrial protein acting as a copper chaperone to cytochrome c 
oxidase (COX) which is crucial for aerobic ATP production(121). We did not elaborate 
on the reason why it gets upregulated after 2-DG treatment. 
GAPDH, Glyceraldehyde 3-phosphate dehydrogenase catalyzes the sixth step of 
glycolysis. It is another important glycolysis enzyme showing decrease in expression 
levels after 2-DG treatment. 
ACADM gene produces acyl-coenzyme A dehydrogenase enzyme that is crucial 
for fatty acid oxidation. During periods of fasting, the cells satisfy their energy need 
from fatty acids. It fits appropriately to the context as we inhibit glycolytic pathway by 
2-DG treatment so that the cells look for alternative energy pathways. 
 
5.1.11.3  Genes related to cell cycle 
 
 CDKN1B gives out the protein cyclin-dependent kinase inhibitor 1B(aka 
p27/kip1). Belonging to the Cip/Kip family of cyclin dependent kinase (CDK) inhibitor 
proteins, it controls cell cycle progression at G1(122). 
 CCNE1 and CCNB2 code for the cyclin family members E1 and B2, 
respectively. Cyclin E1 regulates G1-S transition but it is also shown to be having roles 
in cell proliferation and apoptosis regulation. It overexpression resulted in sensitization 
of hematopoietic cells to radiation(123). Cyclin B2 is also another cell cycle regulator 
which has been found to be upregulated in human cancers. In a 2010 dated study, it is 
observed that its expression levels decreased significantly after therapeutic treatments of 
cancer patients(124). In this study, after 2-DG treatment its expression levels decreased. 
 GADD45- A and B are growth arrest and DNA damage genes that are in charge 
of modulating cell cycle regulation and stress responses(125, 126). 
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5.1.11.4  Genes related to cell growth, proliferation and tumorigenesis 
 
 TPD52 gene produces tumor protein D52. It has been shown to be overespressed 
in ovarian and prostate cancer cells(127, 128). 
 EGR1 codes for early growth response 1 nuclear protein functioning as a 
transcription factor. It serves for transducing the proliferative signal upon its rapid 
induction by growth factors, and it has various roles in cell growth, programmed cell 
death and tumor progression(129). The decrease in the expression levels might mean 
that 2-DG may cause some kind of a growth arrest. 
 BRMS1 has the coding information of breast cancer metastasis-suppressor 1 
protein. Identified in and named after breast cancer cells, this metastasis suppressor 
gene is involved in reducing the metastatic potential, blocking tumor cells’ ability to 
spread and inhibits gene expression in cancer cells(130, 131, 132). The increased 
expression in this study for both WT and p53 -/- HCT 116 cell lines provide an 
interesting and promising result. 
 ING1 gene has the codes for inhibitor of growth protein 1. It is referred to as a 
candidate tumor suppressor(133). Downregulation of ING1 is associated with the 
sensitization of p53-deficient glioblastoma cells to cisplatin induced cell death(134). 
  
Figure 5. 16 Microarray Results: Expresion folds of the genes related to cell cycle. 
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 FRAP1 codes for mammalian target of rapamycin, mTOR. Our western blot 
experiments gave out the decrease in activation of mTOR’s downstream target p70 S6K 
and this is associated with inhibition of mTOR kinase activity(135). However, this is 
also interesting to see that it gets upregulated in the gene level after 2-DG treatment. 
 Cytoplasmic activation/proliferation-associated protein-1 is encoded by 
CAPRIN1 gene. This protein is associated with cellular proliferation, its suppression is 
shown to be responsible for slowing of the proliferation rate and prolongation of the G1 
phase of the cell cycle(136). CAPRIN1 expression levels decreased in this study, which 
might explain the accumulation at G1 phase in cell cycle analysis. 
 It was pleasing to see another familiar name here as we detected HIF1AN 
upregulation. The gene codes for Hypoxia-inducible factor 1-alpha inhibitor (aka FIH-
1). We talked about HIF-1 transcription factor and its effects over glycolysis, cell 
growth etc. The product of this certain gene HIF1AN works as an inhibitor of HIF-1 
alpha therefore inhibiting the activities of a highly studied cancer metabolism related 
gene(137). 
  
 
Figure 5. 17 Microarray Results: Expresion folds of the genes related to cell growth, 
proliferation and tumor formation. 
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6. DISCUSSION AND CONCLUSION 
 
 
 One of the biggest problems of cancer treatment, and probably the most crucial 
one is that the treatments based on killing cancer cells also damage healthy cells in the 
organism. This drawback is eliminated to an extent with radiation therapy where a 
degree of specificity is achieved by localizing the radiation to the tumor(56). However, 
it is still needed to distinguish between cancer cells and normal cells for a treatment to 
provide the ultimate cure. This idea, and the urge for finding better ways to cancer 
treatment introduced some promising targets that specifically selects and affects cancer 
cells. One great target is, as the study of this project, glycolysis which is hailed as one 
of the hallmarks of cancer(53). 
 Starting with the studies of Warburg in the early 20th century and the progress 
coming with his contemporaries, cancer is linked to altered metabolism i.e. cancer cells 
switching to the glycolytic phenotype as they choose it over aerobic respiration for their 
metabolic requirements(1, 2, 3, 4). This altered metabolism is referred to as the 
Warburg Effect. Studying this phenomenon and targeting the Warburg effect in terms of 
an anticancer treatment gained attention and renewed interest in recent years. Glycolysis 
inhibition is infact a promising therapeutic strategy considering the increased 
dependence of cancer cells on glycolysis for their metabolic needs. It also serves for the 
idea of preferential killing of cancer cells without damaging the healthy ones in cancer 
chemotherapy(59).  
 There are various inhibitors and compounds targeting specific enzymes of the 
glycolytic pathway. 2-Deoxyglucose, a synthetic, non-metabolizable analogue of 
glucose is one of these compounds(69). It inhibits phosphorylation of glucose by 
hexokinase. 2-DG itself gets phosphorylated and this causes an accumulation of non-
metabolizable 2-DG-P(59). It is currently at clinical trials.  
In this present study, we chose 2-DG as our glycolysis inhibitor to see the effect 
of glycolysis inhibition as an anticancer strategy. We wanted to work on colon cancer as 
it is one of the most commonly diagnosed cancers. Therefore, colon cancer cell lines 
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HCT 116 WT, p53 -/- and Bax -/- were selected. That left us with the selection of 
anticancer agents. By diving the cell lines into two groups being WT | p53 -/- and WT | 
Bax -/-, we wanted to work on two different anticancer agents. For the first set of cells, 
we selected cisplatin which is a widely used chemotherapy drug exerting its activity by 
damaging DNA(138). For the other set, we went for TNF-related apoptosis-inducing 
ligand (TRAIL) which is a promising candidate for cancer treatments due to its 
therapeutic selectivity by inducing apoptosis through death receptors in malignant 
cells(139). 
 After the determination of dose and time for treatments, we started to 
check out 2-DG effect on the cells. Prior to cisplatin and Killer TRAIL treatments, the 
cells underwent a pretreatment session of 10mM 2-DG for 24 hours. Following this, 
they were given decided concentrations of anticancer agents for 48 hours. The 
expectation was to observe increased cell death due to sensitization of the cells and 
potentiation of the agents. The results were satisfying as cell death responses were 
significantly increased(FIG. 5.3 and FIG. 5.4). However, potentiation by 2-DG showed 
its first requirement: the apoptotic signaling must be over a threshold that is the used 
anticancer agent must start an apoptotic response causing a considerable amount of cell 
death. That is why 2-DG did not potentiate lower concentrations(lower than 12μM) of 
cisplatin. It also did not potentiate Killer TRAIL for HCT 116 Bax -/- cells because of 
no proper apoptosis induction due to that cell line’s resistance. 
 The sensitization effect was further confirmed with the proliferation 
assay for the first set. The DNA content of HCT 116 WT and p53 -/- cells were checked 
after the treatments. 2-DG enhanced the antiproliferative properties of cisplatin, causing 
a significant decrease in DNA content after combined use(FIG. 5.5). We did not 
perform the proliferation assay for the other set because even though 2-DG sensitized 
HCT 116 WT cells to Killer TRAIL-induced cell death, we couldn’t sensitize HCT 116 
Bax -/- cells. Therefore, that set has entered a different path. We wanted to sensitize 
Bax -/- cells and to do that we tried two completely different compounds for different 
purposes. One of them was 3-methyladenine, a compound used for autophagy 
inhibition. This was selected to prevent autophagic cell survival if there ever was. The 
other compound was the BH3 mimetic ABT-737 working as an inhibitor of Bcl-2 and 
Bcl-XL. The idea behind selecting this one was to inhibit Bcl-2 and Bcl-XL, the 
antiapoptotic members of the Bcl-2 protein family, so that their negative regulation of 
apoptosis induction could be stopped if they were responsible. However, in both cases 
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HCT 116 Bax -/- cells showed that same resistance to Killer TRAIL(FIG. 5.6). 
Treatment of HCT 116 WT cell lines with the same compounds did not provide 
anything either(FIG. 5.7). 
To check the apoptosis markers on protein level, we performed western blotting 
experiments. We decided to look for caspase 3 activation for the first set and caspase 8 
activation for the second because cisplatin and Killer TRAIL induce apoptosis by 
different pathways. Cisplatin induces apoptotic signaling via intrinsic (mitochondrial) 
pathway whereas Killer TRAIL cause apoptosis from extrinsic pathway through death 
receptors. Each experiment showed caspase cleavage therefore confirming apoptosis 
induction(FIG. 5.8). BID, a proapoptotic member of Bcl-2 protein family, was also 
checked for the second set as caspase 8 activation cause the truncation of BID. HCT 
116 Bax -/- cells did not show apoptosis induction as BID remained intact in all the 
samples, unlike HCT 116 WT. 
BID opened the way for the idea of taking a look at some of the Bcl-2 protein 
family members. At this part of the study, we left the anticancer agents behind us and 
put the emphasis on 2-DG alone to understand the mechanisms as to how it sensitizes 
the cells to the anticancer agents. With the very first try we obtained an important result 
with Mcl-1, one of the antiapoptotic members of the family. 2-DG treatment caused a 
decrease in Mcl-1 protein levels for all three cell lines, HCT 116 WT, p53 -/- and Bax -
/-(FIG. 5.9). This was the second successful step after the flowcytometric analysis of the 
sensitization effect of 2-DG. At this point we thought of Mcl-1 as the highly possible 
key player of the sensitization effect, because of its unique properties unlike other 
antiapoptotic members. A detailed literature research gave us the reason why Mcl-1 
could be so important: first it has a very short life which helps for its being highly 
regulated and second in the name of its role in apoptosis regulation Mcl-1 is beyond 
other antiapoptotic members because its expression can be stimulated by growth factors 
and it has connections to cell cycle control(103). These attributes make it a pivotal 
survival protein having roles in normal animal development(140).  We also leaned over 
some other Bcl-2 family members that have interaction to Mcl-1. However, protein 
levels of antiapoptotic Bcl-2 and proapoptotic Bim and Bax were all unaffected(FIG. 
5.9).  
Assessment of ATP levels was always in our minds just to show the effect of 2-
DG over the energy metabolism. We performed ATP assay with all three cell lines after 
24 hours of 2-DG treatment. But here, the ATP concentrations showed very little or no 
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decrease. Therefore, we wanted to see an early response and checked the changes after 5 
hours of 2-DG treatment(FIG. 5.10). For this condition, ATP concentrations were 
decreased 20% in each cell line. Actually we expected a decrease for 24-hour treatment 
as well in the first place. However, the medium used for the cells (McCoy’s 5A 
modified medium) had glucose and L-glutamine as ingredients. 2-DG effectiveness is 
affected to an extent by the presence glucose as both compete for phosphorylation, and 
there was also something we underestimated: the alternative energy sources such as 
fatty acids and amino acids(especially L-Glutamine)(59). Therefore, the cells probably 
overcame the ATP depletion by alternative energy pathways, however, the ATP 
depletion in the early hours did actually turn into signals. With western blotting 
experiments, we wanted to confirm the ATP decrease by checking the phosphorylation 
level of AMPK, the energy sensor protein. Phospho-AMPK levels increased after 2-DG 
treatment (FIG. 5.10) for all three cell lines which was what we wanted, because when 
ATP levels decrease AMPK gets phosphorylated(activated) and signals for this stress 
condition(31). Being an ancient metabolic regulator found in all eukaryotes, AMPK 
couples energy status to growth signals(32, 1). It provides a metabolic checkpoint and 
regulates the cellular response to energy availability(1). One other feature is that it 
inhibits mTOR resulting in inhibition of cell proliferation under energetic stress 
conditions. This makes AMPK signaling another candidate mechanism for 2-DG-
induced sensitization. Apart from confirming the ATP decrease, AMPK activation also 
led us to check the mTOR pathway as it was shown to be responsible for mTOR 
inhibition in a similar study(36). 
To check the mTOR inhibition we had several alternative ways. mTOR 
signaling regulates cell growth, proliferation, metabolism and survival by controlling 
protein synthesis(mRNA translation, ribosomal biogenesis)(43). mTOR directly 
phosphorylates ribosomal protein S6 kinase(p70 S6K), eukaryotic initiation factor 4E 
binding protein 1(4E-BP1) and eukaryotic elongation factor 2 kinase(EEF2K), all of 
which have crucial roles in protein synthesis and help mTOR in the regulation of cell 
growth(43). Coming from this point, a possible mTOR inhibition should decrease the 
phosphorylation levels of these three regulators. We were thinking of performing a 
western blot, and p70 S6 kinase was selected because of its importance as a translation 
regulator(37). Figure 5.11 has the results of the western blot experiment, phospho-p70 
S6K antibody was used to detect activated p70 S6 kinase. It was decreased for all cell 
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lines’ 2-DG samples, confirming the inhibition of mTOR as the phosphorylated p70 S6 
kinase protein levels were reduced. 
Considering the potential connection of Mcl-1 to cell cycle control, we 
performed cell cycle analysis in order to see the distribution and how 2-DG treatment 
did affect the overall process. All cell lines showed further accumulation at G1 phase in 
comparison to control samples, suggesting a cell cycle arrest at this phase(FIG. 5.12). 
p53 has well known functions in controlling cell cycle arrest, so we checked its protein 
levels. It was not present in HCT 116 p53 -/- cells, but it showed a decrease in other cell 
lines. Absence in one and reduction in the other two kept it in discussions that p53 
might play an important role. We did a literature search about p53 roles in cell cycle 
control and metabolism to obtain details. What we got out of this is that p53 gets in 
contact with AMPK and mTOR. It works together with AMPK for the induction of a 
cell cycle check point, causing cell cycle arrest under energy related stress 
conditions(46). Also, p53 interacts with mTOR in the regulation of cell growth. Down-
regulation and/or absence of p53, on the other hand might be understood as a 
contribution to cancer cells in the name of reducing (or eliminating) the guardian of the 
cell, the tumor suppressor. And inactivation of p53 is like a common feature in many 
cancers, however its absence under a metabolic stress condition may sensitize the tumor 
cells(54). In the end it all comes down to the double nature of p53, again. 
To make sure about the contribution of Mcl-1 to 2-DG-induced sensitization 
effect, we performed overexpression experiments. We did transient transfection of HCT 
116 WT and p53 -/- cells with an Mcl-1 overexpression vector and then we followed the 
same treatment procedures with 2-DG and cisplatin. The results were highly successful 
as Mcl-1 overexpression resulted in a significant decrease in cell death numbers(FIG. 
5.13). With this result, Mcl-1 guaranteed its place in this study as the leading actor of 
the sensitization effect. 
RNA Microarray analysis was done to provide us information on the changes of 
gene expression levels after 2-DG treatment. Control and 2-DG treated RNA samples 
from HCT 116 WT and p53 -/- were analyzed. The selected genes were divided in four 
groups in terms of their activity: apoptosis related, cell cycle related, metabolism related 
and growth-proliferation-tumorigenesis related. The list was created with the following 
criteria: a p-value for differential gene expression of 0.05 or better and changes that 
happened in both WT and p53 -/- samples. Apart from the list, we did not observe the 
names of Mcl-1 and p53 among the genes, this gave us the idea that the changes for 
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these most probably happened at the protein level. AMPK activation is shown to cause 
Mcl-1 block in translation(36). And also there is the fact that mTOR inhibition should 
cause problems at protein synthesis. A 2009 dated paper stated that AMPK-mTOR 
pathway controls Mcl-1 levels by controlling its translation(36). We also showed 
AMPK activation and mTOR inhibition correlating with their findings. 
Going back to the actual list under the group of apoptosis related genes(FIG. 
5.14), we observed that 2-DG induced the expression of caspases 2 and 3 along with 
programmed cell death proteins 2, 5 and 6. It also induced the expression of two 
proapoptotic Bcl-2 family members Bcl-AF1 and BID. These can be explained as a 
preparation for apoptotic signaling. 
There were a couple of highly important metabolic enzymes in the list of genes 
related to cellular metabolism(FIG. 5.15). Hexokinase 2 downregulation was spot on as 
the first enzyme of glycolysis got downregulated after 2-DG treatment. GAPDH and 
LDHA were the other glycolytic enzymes showing downregulation. ACADM 
upregulation was the confirmation of the cells’ search for alternative energy sources as 
it is important for fatty acid oxidation. TIGAR, negative regulator of glycolysis was 
upregulated. Pyruvate dehydrogenase kinase (PDK3) was downregulated, it is an 
important enzyme contributing to glycolysis by phosphorylating and inactivating 
pyruvate dehydrogenase complex which converts pyruvate into Acetyl-CoA. COASY 
and SCO2 upregulation might mean some kind of a revival in the mitochondrial energy 
pathway, forcing the cells to go for oxidative phosphorylation. This also made us think 
of ROS production as a cause of sensitization to apoptosis because of the sudden 
abnormal activation of the mitochondrial energy pathway. p53 has roles in the 
regulation of oxidative phosphorylation and ROS production as well as activating an 
antioxidant response against oxidative stress(54). A reduction in (or absence of) p53 
protein levels may cause inability to prevent ROS production. These all suggest that 2-
DG causes serious changes in the expression of some important metabolic enzymes and 
it basically targets cellular metabolism. 
Cell cycle related genes showed downregulation(FIG. 5.16): CDKN1B, CCNE1, 
CCNB2, GADD45A, GADD45B. Growth arrest and DNA damage(GADD45) genes 
are shown as p53 targets and they are responsible for cell cycle arrest control(45). The 
effect on cell cycle should be studied in details as dysregulation of the cell cycle might 
contribute to sensitization. In this study, we had shown cell cycle arrest at phase G1 
after 2-DG treatment. 
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HIF1 alpha came into prominence out of the list of genes related to cell growth-
proliferation-tumorigenesis(FIG. 5.17). We did not observe its name among the genes 
actually, so there was not any indication of it being upregulated or downregulated. 
However, we observed the upregulation of HIF1AN (aka FIH-1) which inhibits the 
activity of HIF1(13). HIF1, hypoxia-inducible factor 1, works as a transcription factor 
regulating glucose metabolism by stimulating glytcolytic energy production by 
transactivating genes such as LDH and PDK(which can be spotted in our list under 
genes related to cell metabolism), but it also regulates glycolysis by downregulating 
oxidative phosphorylation within the mitochondria(13). Therefore, considering the 
upregulation of HIF1AN, we can say that 2-DG treatment causes HIF-1 inhibition via 
the induction of its inhibitor. This in turn results in the downregulation of glycolytic 
enzymes and upregulation of some mitochondrial metabolic enzymes. HIF-1 inhibition 
might also relate to ROS production as when it is active it is responsible for the 
decreased mitochondrial function meaning decreased ROS production(13). In this case, 
HIF-1 inactivation may cause an increase in the formation of reactive oxygen species. 
HIF-1 interacts with both mTOR and p53. mTOR is actually an upstream 
activator of HIF-1, seeing both getting inhibited after 2-DG treatment is so appropriate. 
HIF-1’s interaction with p53 has been shown as low level of p53 attenuates HIF-1 
transactivation(141). 
The other significant gene expression changes were the suppression of 
proliferation-tumorigenesis related genes such as CAPRIN1, TPD52, EGR1, ING1 and 
the potential causes of these changes are slowing of the proliferation rate and growth 
arrest. mTOR showed an upregulation in the gene level which was interesting and might 
be some kind of a recovery mechanism to take over following its inhibition at protein 
level. Another interesting finding was to observe BRMS1, a tumor suppressor, getting 
upregulated after 2-DG treatment. This metastasis suppressor gene may contribute to 
the sensitization effect. 
Collectively, these results gave an idea of how 2-DG sensitizes HCT 116 colon 
cancer cell lines and potentiates apoptosis inducer anticancer agents, cisplatin and Killer 
TRAIL. AMPK activation, mTOR inhibition, HIF-1 inhibition, cell cycle arrest, Mcl-1 
downregulation all contribute to the sensitization effect from various perspectives(FIG. 
6.1). 
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Coming all the way from Warburg’s first observations, targeting cancer 
metabolism has gained renewed interest in cancer therapy. Glycolytic inhibitors is now 
seen as potential anticancer agents. Several of them are already at various stages of pre-
clinical and clinical development(10). With each new study over the Warburg effect, 
cancer cell metabolism is explored deeper and so making it even more exciting for 
designing new therapeutic methods that might ultimately give what scienctist want: win 
the war against cancer. 
 
 
 
 
 
Figure 6. 1 A Schematic Presentation as to how 2-Deoxyglucose Treatment Effect Certain 
Signaling Pathways Leading to Sensitization of Cancer Cells. 
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7. FUTURE STUDIES 
  
 
Clinical significance of cancer’s glycolytic phenotype has proved itself with the 
development of F-fluorodeoxyglucose positron emission tomography (F-FDG-PET). It 
gave an enormous contribution to cancer treatment as the system bases itself upon 
cancer cells’ increased glucose uptake and metabolism. Relying on the Warburg effect, 
F-FDG-PET is used successfully in the diagnosis, staging and prognosis of cancer(53). 
After  the injection of radioactive pharmaceutical fluorodeoxyglucose (FDG), the sister 
molecule of 2-DG, PET scanner forms images of the distribution of FDG around the 
body. FDG, just like 2-DG, is an anti metabolic glucose analog. Once it gets inside the 
cells and gets phosphorylated, it can not be further metabolized. Therefore it causes an 
accumulation of phosphorylated FDG molecules inside the cells with higher glucose 
uptake. 
The use of F-FDG-PET scan in clinical oncology consolidates glycolytic 
metabolism as one of cancer’s most vulnerable phenotype. Therefore, targeting cancer 
cell metabolism is as promising as ever. Glycolysis inhibition proves itself as a 
promising therapeutic anticancer strategy. More clinical studies should be done for the 
further development of this strategy. 
For the future of this particular study, we are thinking of expanding it to several 
other cancer cell lines such as breast cancer cells and leukemia cells. We are 
considering to work on other glycolysis inhibitors as well for comparative analysis. If 
we go into some specific details, the role of hypoxia inducible factor 1 (HIF-1) should 
be analyzed thoroughly. The proteins responsible for cell cycle control should be 
studied in order to understand their contribution to cellular metabolism. And of course 
we will select and go for the genes that came out of our microarray analysis, especially 
the ones that are related to cell growth and tumorigenesis. There can be some important 
aspects hiding in the background but responsible for cancer cells’ metabolic switch. 
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APPENDIX A 
 
 
Name of Antibody   Supplier Company  Catalog Number 
 
2-Mercaptoethanol    Fluka, Switzerland    63700  
Acrylamide/Bis-Acrylamide   Sigma, Germany    A3699  
Agarose     AppliChem, Germany    - 
Ammonium persulfate   Sigma,  Germany    A3768-25G  
EDTA      Riedel-de Haén, Germany   27248  
Ethanol     Riedel-de Haén, Germany   32221  
Glycine     Molekula, UK     M10795955  
HCl      Merck, Germany    100314  
Hepes      Molekula, UK     M55704197  
Isopropanol     Merck, Germany    1009952500  
KCl      Fluka, Switzerland    60129  
KH2PO4     Riedel-de Haén, Germany   4243  
Liquid nitrogen   Karbogaz, Turkey    - 
Methanol     Sigma-Aldrich    24229  
Na2HPO4     Merck, Germany   1065791000  
NaCl      Duchefa Biochemie    S05205000  
Phosphatase Inhibitor coctail tablet Roche, Germany    4906837001 
PMSF      Amresco®,USA    0754-25G  
Protease Inhibitor coctail tablet  Roche, Germany    4693124001  
TEMED     Sigma, Germany    T7024-100ml  
Tris      Molekula, UK     M11946779  
Trypsin/EDTA    PAN, Germany    P10-0231SP  
Tween 20     Molekula, UK     18945167  
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APPENDIX B 
 
 
Name of Antibody   Supplier Company  Catalog Number 
 
Anti Mcl-1    Cell Signal Tech., USA   4572 
Anti Bcl-2    Cell Signal Tech., USA  2870 
Anti Bim    Cell Signal Tech., USA  2933 
Anti BID    Cell Signal Tech., USA  2002 
Anti β-Actin    Cell Signal Tech., USA  4970 
Anti p53    Cell Signal Tech., USA  9282 
Anti Bax    Cell Signal Tech., USA  2772 
Anti cleaved caspase 3   Cell Signal Tech., USA  9661 
Anti caspase 8    Cell Signal Tech., USA  9746 
Anti Phospho-AMPKα (Thr172) Cell Signal Tech., USA  2535 
Anti Phospho-p70 S6 Kinase   Cell Signal Tech., USA  9234 
(Thr389) 
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 Appendix C 
 
 
Name of Material   Supplier Company  Catalog Number 
 
ECL Advance Chemiluminescence Amersham Biosciences, UK   RPN2135 
Blocking agent   ECL Advanced TM blocking agent  CPK1075  
Hyperfilm ECL    Amersham Biosciences, UK   RPN2103K 
PVDF membrane    Roche, Germany    3010 
Developer Solution    Agfa, USA     - 
Bradford Solution   Biorad Inc., USA    500-0006 
Whatman Papers    -     - 
Page Ruler Prestained Ladder   Fermentas, Germany    #SM1811 
Plasmid pCMV-Flag-hMcl-1  Addgene    25392 
McCoy’s 5A Medium (Modified) Pan Biotech, Germany   - 
Fetal Bovine Serum   PAN, Germany   - 
Penicilin/Streptomycin   PAN, Germany    P06-07100  
Genopure Plasmid Midi Kit  Roche     03143414001 
X-tremeGENE 9 Reagent  Roche     - 
CyQUANT Cell Prolif. Assay  Invitrogen    - 
ATP Bioluminescence Assay  Roche     11699709001 
Kit HS II 
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Appendix D 
 
 Part of Figure 5.1: Detailed flow-jo graphs of populations selected for analysis 
and the histograms showing the shift in the intensity of fluorescence dye between 
control and cisplatin treated cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
86 
 
 
 
 
87 
 
Part of Figure 5.2:                                                                                                                                 
Detailed flow-jo graphs of populations selected for analysis and the histograms showing 
the shift in the intensity of fluorescence dye between control and cisplatin treated cells. 
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 Part of Figure 
5.3: Detailed flow-
jo graphs of 
populations 
selected for 
analysis and the 
histograms 
showing the shift 
in the intensity of 
fluorescence dye 
between control 
and cisplatin 
treated cells. 
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Part of Figure 5.4:                                                                                                                                 
Detailed flow-jo graphs of populations selected for analysis and the histograms showing 
the shift in the intensity of fluorescence dye between control and cisplatin treated cells. 
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Part of Figure 5.6 – 5.7:                                                                                                                                 
Detailed flow-jo graphs of populations selected for analysis and the histograms showing 
the shift in the intensity of fluorescence dye between control and cisplatin treated cells. 
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Part of Figure 5.13:                                                                                                                                 
Detailed flow-jo graphs of populations selected for analysis and the histograms showing 
the shift in the intensity of fluorescence dye between control and cisplatin treated cells. 
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